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ABSTRACT 
MARTILIAS STEPHEN FARRELL: Pharmacosynthetics and the Cell-Type-Specific 
Control of Neuronal Signaling 
(Under the direction of Bryan L. Roth) 
 
Pharmacology, in its broadest interpretation, is defined as the study of drug action. In 
modern neuropsychopharmacology, there is a conceptual boundary between the “drug” and 
the “action”, with the drug itself on one side and signal transducer (receptor), the signal 
transduction cascade (effector proteins, second messengers), the cellular response 
(transcriptional regulation, activity modulation), the organ response (brain circuitry 
modulation), and, finally, the whole organism response (behavior) on the other. In other 
words, pharmacology has structured itself around the idea that the exogenous molecule (the 
drug) encodes a “signal” leading to everything on the other side including, in extreme 
instances, a physiological response. The inference is that engaging a particular signal 
transduction pathway in a defined cell type leads inexorably to a prototypic physiological 
response. Here, I suggest that the invention of synthetic ligand—GPCR pairs (aka 
DREADDs, RASSLS, ‘pharmacogenetics’) permits the study of pharmacology using a 
shifted equation: with the signal transduction elements moved to the left and, subsequently, 
under experimental control. For the purposes of disambiguation and to clarify this approach 
as a creation of pharmacological manipulation, I present the term pharmacosynthetics to 
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describe what has heretofore been called pharmacogenetics or chemicogenetics. In this 
document I will review previous work utilizing this technology, present my work validating a 
variation of this technology in a heretofore untested cellular context, and provide a 
perspective on how this technology can advance the field of pharmacology. 
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I dedicate this dissertation to my future wife Candace and my parents.  
 vi 
ACKNOWLEDGEMENTS 
First and foremost, I would like to acknowledge Dr. Bryan Roth for providing time, 
guidance, and resources throughout my dissertation research. Bryan instilled within me 
scientific faculties that I did not possess prior to joining his lab, and I am grateful for his 
persistence in shaping me into a young scientist.  
My dissertation research was performed with the assistance and guidance of many great 
scientists, and I wish to acknowledge them here. Members of the Roth Lab, present and past, 
were invaluable to my dissertation. Prem Yadav, Jon Allen, Atheir Abbas, Ryan Strachan, 
Sarah Rogan, Sandy Hufeisen, Tom Mangano, Neils Jensen, Xi-Ping Huang, Heong-min 
Lee, and Vince Setola directly helped me along the way in some fashion, and the other 
members of the lab were fantastic colleagues. I would also like to thank Tanya Daigle, Marc 
Caron, Yehong Wan, and Nicole Calakos of Duke University for their collaborations.  
I would like to thank the members of my dissertation committee, Ken McCarthy, Thom 
Kash, Regina Carelli, and particularly my chair, David Siderovski, for their support and 
insight over the course of my graduate student career. I would also like to again thank David 
Siderovski for providing feedback during the qualifying examination process. I would also 
like to thank Lee Graves, Ken Harden, and Rob Nicholas for recruiting me to the UNC 
Pharmacology department. I would also like to thank John Sondek and for an excellent 
rotation during the first year of my studies. Furthermore, I’d like to thank Linda Dykstra for 
her support and enthusiasm for my research.  
 vii 
I’d like to thank Gary Johnson for shaping an excellent department in which to receive 
doctoral training. I’d also like to thank members of the administrative staff, particularly 
Eddie Gill and Chris Turner, for making my NRSA fellowship application process incredibly 
simple. I’d also like to thank the National Institute of Mental Health for the honor of being 
awarded the National Research Service Award, an investment that I hope I can return to 
society through a successful scientific career.  
I’d like to specifically thank Dan Urban for his comradery during our graduate school 
career. When we first rotated in the Roth lab together, we both somehow knew that neither 
was competing to one-up the other, and our tenure in the lab since then has been one of 
support, encouragement, and endless scientific conversation. In Dan I have found an amazing 
colleague and friend, and I wish to acknowledge him for being awesome.  
Finally, I would like to thank my family and friends for their love and support over the 
past 6 years. From the countless pickups and drop offs at the airport or train station, to those 
of you that made the drive down to visit the Paris of the South, I extend my gratitude.  
The past 6 years have been filled with ups and downs, and I extend my gratitude to all 
for co-creating this experience.  
 
 viii 
TABLE OF CONTENTS 
TABLE OF CONTENTS .................................................................................................. viii 
LIST OF TABLES .............................................................................................................. xi 
LIST OF FIGURES ............................................................................................................ xii 
LIST OF ABBREVIATIONS ............................................................................................ xiii 
LIST OF SYMBOLS........................................................................................................ xvii 
CHAPTER 1. BACKGROUND ............................................................................................1 
1.1. INTRODUCTION ......................................................................................................1 
1.2. APPLICATION OF PHARMACOSYNTHETICS ......................................................6 
1.2.1. Selective mimicry of endogenous receptors ..........................................................6 
1.2.2. Creating drug-like modulation where none exists .................................................7 
1.2.3. Encoding and modulating diffuse neuronal ensembles ........................................ 10 
1.2.4. Long-lasting specific neuronal modulation ......................................................... 11 
1.3. CONSIDERATIONS AND IMPLICATIONS OF THE  
       PHARMACOSYNTHETIC APPROACH ................................................................ 12 
1.3.1. Expression systems ............................................................................................ 12 
1.3.1.1. Virally Mediated Gene Transfer .................................................................. 12 
 ix 
1.3.1.2. Genomic Insertion of Transgene .................................................................. 13 
1.3.1.3. Combinatorial approaches ........................................................................... 17 
1.3.2. CNO Doses and Routes of Administration ......................................................... 17 
1.4. LIMITATIONS OF CURRENT PHARMACOSYNTHETIC TECHNOLOGY ........ 18 
1.4.1. Pharmacological vs. Physiological Manipulation ................................................ 18 
1.4.2. Limitations of Technology ................................................................................. 19 
1.5. CONCLUSIONS ...................................................................................................... 20 
1.5.1. Key Differences Between Optogenetics and Pharmacosynthetics ....................... 20 
1.5.2. Concluding remarks ........................................................................................... 22 
CHAPTER 2. NEURONAL VALIDATION OF GS COUPLED DREADD (RM3DS)........ 23 
2.1. INTRODUCTION .................................................................................................... 23 
2.2. THE STRIATUM AS AN IDEAL REGION FOR TESTING  
       SELECTIVE CONTROL OF NEURONAL SIGNALING IN  
       DEFINED NEURONAL POPULATIONS. .............................................................. 24 
2.3. METHODS............................................................................................................... 26 
2.4. RESULTS ................................................................................................................ 39 
2.4.1. Generation and characterization of adora2A-rM3Ds mice .................................. 39 
2.4.2. CNO-induced modulation of locomotion in adora2A-rM3Ds mice ..................... 43 
2.4.3. CNO-induced modulation of amphetamine sensitization .................................... 43 
CHAPTER 3. GENERAL DISCUSSION, IMPLICATIONS,  
                       AND FUTURE DIRECTIONS...................................................................... 46 
 x 
3.1. DISCUSSION .......................................................................................................... 46 
3.2. IMPLICATIONS ...................................................................................................... 48 
3.2.1. Regarding Technological Validation .................................................................. 48 
3.2.2. Regarding Neurobiological Findings .................................................................. 49 
3.3. FUTURE DIRECTIONS .......................................................................................... 50 
3.3.1. Future technological development ...................................................................... 50 
3.3.1.1. A non CNO-based DREADD ...................................................................... 50 
3.3.1.2. Enhanced genetic expression strategies........................................................ 51 
3.3.1.3. Complete experimental control of signal transduction.................................. 51 
3.3.2. Future Applications of Pharmacosynthetic Technology ...................................... 52 
3.3.2.1. Non-interfering modulation ......................................................................... 52 
3.3.2.2. Cell-type specific GPCR signaling vs. “activation” and “silencing” ............. 54 
3.3.3. Future Neurobiological Directions ..................................................................... 58 
3.4. FINAL WORDS: ...................................................................................................... 58 
APPENDIX A. TABLES .................................................................................................... 60 
APPENDIX B. FIGURES ................................................................................................... 64 
REFERENCES.................................................................................................................... 86 
 xi 
LIST OF TABLES 
 
Table 1: Summary of neuronal DREADD applications to date. ............................................ 60 
Table 2: Baseline Behavior Activity .................................................................................... 62 
Table 3: Baseline Morris Water Maze: ................................................................................ 63 
 xii 
LIST OF FIGURES 
Figure 1: Properties and Composition of Currently Utilized DREADDs. ............................. 65 
Figure 2: Creation and validation of adora2A-rM3Ds mice. ................................................. 67 
Figure 3: rM3Ds is expressed in striatopallidal neurons in adora2A-rM3Ds mice. ............... 69 
Figure 4: Additional immunohistochemistry images comparing a  
         wild-type mouse with an adora2A-rM3Ds transgenic mouse. ............................... 70 
Figure 5: CNO activates canonical Gαs-type signaling in adora2A-rM3Ds mice. ................. 71 
Figure 6: pErk1/2 and pAkt308 signaling in adora2A-rM3Ds mice. ..................................... 73 
Figure 7: Cocaine-induced signaling in wild-type and adora2A-rM3Ds mice. ...................... 74 
Figure 8: Results of baseline behavior screen....................................................................... 75 
Figure 9: Endogenous Gs signaling is intact in adora2A-rM3Ds mice. ................................. 77 
Figure 10: CNO administration inhibits locomotor activity in adora2A-rM3Ds mice. .......... 78 
Figure 11: CNO administration modulates amphetamine-induced physiological changes. .... 79 
Figure 12: Replication in second founder line. ..................................................................... 81 
Figure 13: Shifting the pharmacological equation. ............................................................... 83 
Figure 14: An application of pharmacosynthetics in drug discovery. .................................... 85 
 xiii 
LIST OF ABBREVIATIONS 
A2A – Adenosine A2A receptor 
AAV – adeno-associated virus 
adora2A – Adenosine A2A receptor gene 
AgRP – agouti-related protein 
AKT, pAKT – Protein Kinase B (PKB), phosphorylated 
AMPAR – alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor 
AMPH – Amphetamine 
ANOVA – Analysis of Variance 
ARC – arcuate nucleus 
ATP – adenosine triphosphate 
BAC – Bacterial Artificial Chromosome 
BCA – Bicinchoninic acid assay 
bp – base pair 
BSA – Bovine Serum Albumin 
cAMP: cyclic adenosine monophosphate 
CNO – Clozapine N-oxide 
D1-Dopamine receptor 1 
 xiv 
D2 – dopamine receptor 2 
DARPP-32: Dopamine and cAMP regulated neuronal phosphoprotein 
dB – decibels 
DMEM – Dulbecco’s Modified Eagle Medium 
DMSO – Dimethyl Sulfoxide 
DNA – Deoxyribonucleic Acid 
Drd1 – Doparmine Receptor D1 
Drd2 – Doparmine receptor D2 
DREADD – Designer Receptors Exclusively Activated by Designer Drug 
EGFP – enhanced green fluorescent protein 
EPSCs – Excitatory postsynaptic currents 
ERK, pERK – Extracellular signal regulated kinase, phosphorylated 
Flp – Flippase 
FRT – Flippase recognition target 
FW – Forward 
GDP – guanosine diphosphate 
GENSAT – Gene Expression Atlas of Mouse Central Nervous System 
GPCR: G protein-coupled receptor 
GTP – guanine triphosphate 
 xv 
HBSS – Hank’s Buffered Salt Solution 
HEK  - human embryonic kidney cells 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
hM3Dq – Human Muscarinic Receptor 3 Gq DREADD 
hM4Di – Human Muscarinic Receptor 4 Gi DREADD 
i.p. – intraperitoneally 
IRES – Internal Ribosome Entry Site 
kb: kilobase 
mEPSC: miniature excitatory post synaptic current 
MeSH – Medical Subject Headings 
Min – minutes 
MSN: medium spiny neuron 
NAc – Nucleus accumbens 
NIH – National Institutes of Health 
NINDS – National Institute of Neurological Disorders and Stroke 
NMDAR – N-methyl-D-aspartate receptor 
NREM: Non Rapid Eye Movement 
P23 – Post Natal Day 23 
PAGE – Polyacrylamide Gel Electrophoresis 
 xvi 
PBS – Phosphate Buffered saline 
PCR – Polymerase Chain Reaction 
PDZ – post synaptic density protein (PSD95), Drosophila disc large timor suppressor 
(Dlg1), and zonula occludens-1 protein(zo-1) domain 
PKA – protein kinase A 
PLSD – Fisher’s protected least-significant difference 
Rbp4: retinol binding protein 4 
REV – Reverse 
RFP – Red Fluorescent Protein 
rM3Ds – Rat Muscarinic Receptor 3 Gs DREADD 
Rpm – revolutions per minute 
RT – Room temperature 
SDS – Sodium Dodecyl Sulfate 
TBST – Tris Buffered Saline with 0.05% Tween 20 
TRE – Tetracycline Response Element 
tTa – tetracycline transactivator 
 
 xvii 
LIST OF SYMBOLS 
Gα – G protein alpha. 
Gβ/γ – G proteins beta and gamma 
Gαs – Gs-type G protein alpha – stimulates adenylyl cyclase 
Gαolf – G alpha olf, a Gs-type G protein 
Gαi – Gi-type G protein alpha – inhibits adenylyl cyclase 
Gαq – Gq type G protein alpha – stimulates phospholipase C 
 
CHAPTER 1. BACKGROUND 
1.1. INTRODUCTION 
The gap between our understanding of receptor mediated signaling and the ultimate 
functional output of the brain is shrinking. The past decade has witnessed the advent of 
multiple technologies that allow the exquisite manipulation of neurons in an intact animal, 
providing the opportunity to definitively determine the neuronal correlates of complex brain 
function. The primary technologies are optogenetic – the modulation of transgenic receptors 
and channels via photons-- and pharmacogenetic – the modulation of transgenic receptors via 
pharmacologic agents. Here I will focus on pharmacogenetics.  
First and foremost, I present an alternative name for this technology to disambiguate the 
topic from other uses of the word pharmacogenetic. The term “pharmacogenetic” is already 
an established MeSH (Medical Subject Headings) term, defined as “a branch of genetics 
which deals with the genetic variability in individual responses to drugs and drug 
metabolism”. This word has been well adopted, retrieving 3417 results from PubMed as of 
October 10
th
, 2012, has been in use for an extended period of time (Gonzalez-Vacarezza et 
al, 2012; La Du, 1972; Weinshilboum et al, 1999) and is cited as the foundation of 
personalized medicine (Cohen, 1997; Kohane, 2012). For similar reasons, the term “chemical 
genetics” (or its portmanteau chemicogenetic), while not being assigned its own MeSH term, 
has been defined as “the study of gene-product function in a cellular or organismal context 
using exogenous ligands” (Stockwell, 2000). Here I present an alternative terminology and 
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reimagination of pharmacogenetics (the modulation of transgenic receptors via 
pharmacologic agents) as pharmacosynthetics. This term integrates the true meaning and 
functional mechanisms of the technology: pharmaco- meaning drug and -synthetic meaning 
the combination of two or more parts in an artificial manner. Pharmacosynthetics provides a 
clear distinction from both pharmacogenetics and chemicogenetics and, to date, has not been 
used to describe any phenomenon or identify any technology.  
I present the formal definition of pharmacosynthetics as “a branch of biology which 
deals with the creation of pharmacological modulation using artificial components”. While it 
is possible to equate conventional drugs with pharmacosynthetics (or having been developed 
through pharmacosynthesis), there are distinctions within the semantics that should be 
explored to provide clarification. A chemical is synthesized to have a particular 
pharmacology, and this pharmacology is based on the system with which that chemical 
interacts. On the other hand, a pharmacosynthetic approach creates pharmacological 
modulation within a system using artificial components. While a pharmacological agent may 
be synthesized, at no point in this effort is the pharmacology of the agent created – instead, it 
is measured. In one way of thinking about it, a pharmacology (as defined as the study of drug 
action) is engineered for an otherwise inert chemical by engineering a receptor and inserting 
the receptor into a living system. On the other hand, when a novel chemical is synthesized, 
its pharmacology in a living system is studied to determine whether or not it is a drug or has 
drug-like properties.  
The pharmacosynthetic tools currently utilized include the Designer Receptors 
Exclusively Activated by Designer Drug (DREADDs), the latest iteration of a long-standing 
concept of creating orthologous ligand-receptor pairs to remotely control cellular GPCR 
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signaling (Conklin et al, 2008). The original DREADDs were human muscarinic 
acetylcholine receptors engineered to be activated by clozapine N-oxide (CNO), an otherwise 
inert pharmacological agent. Additionally, DREADDs are insensitive to the endogenous 
ligand, acetylcholine. There are currently three DREADDs in common use – the hM3Dq that 
activates Gαq signaling, the hM4Di that activates Gαi signaling, and the rM3Ds that activates 
Gαs signaling. These three DREADDs share the same point mutations (Figure 1) that 
simultaneously engender CNO efficacy and acetylcholine inefficacy (Armbruster et al, 
2007). The rM3Ds was engineered to couple Gαs by replacing intracellular loops 2 and 3 of 
the hM3Dq with those from the turkey β1-adrenergic receptor (Guettier et al, 2009). With 
these three DREADDs, it is possible to control 3 of the G protein signaling cascades found in 
the mammalian brain.  
Other pharmacosynthetic tools have been developed in addition to DREADDs. The 
precursor to DREADDs, the Receptors Activated Solely by Synthetic Ligand (RASSL), were 
also G protein-coupled receptors that had been engineered to respond to synthetic ligands 
instead of their cognate ligand (Conklin et al, 2008). These receptors required the use of a 
knockout background of the parent receptor because the synthetic ligand still activates the 
native receptor. Additionally, these receptors often exhibited constitutive activity, rendering 
temporal control of signaling intractable. Another GPCR system is the allotstatin receptor 
(AlstR) and ligand, consisting of the D. melanogaster neuropeptide allostatin and its cognate 
receptor (Gosgnach et al, 2006). The system confers Gi/o signaling and can silence neurons 
through GIRK channel modulation. This system provides temporal and spatial control similar 
to DREADDs, but is more invasive due to the requirements of local microinjection of a 
neuropeptide. In addition to G protein modulation, pharmacosynthetic tools exist that 
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modulate ion conductance via ligand gated ion channels. Namely, the pharmacologically 
selective actuatory modules (PSAMs) and their cognate pharmacologically selective effector 
molecule (PSEM) agonists (Magnus et al, 2011) have been shown to be effective neuronal 
modulators. This system permits for the direct modulation of ion conductance via 
pharmacological means using chimeras of ligand-binding domains of the alpha7 nicotinic 
acetylcholine receptor and ion pore domains of other Cys-loop receptors. Similar to 
DREADDs, PSAMs were engineered to respond to PSEMs in a two-way selective manner, 
providing for exclusive control of neuronal signaling. Additionally, ivermectin-gated ion 
channels provide similar modulation of membrane ion conductance using glutamate-gated 
chlorid channel receptor (GluClR) activated by ivermectin (Lerchner et al, 2007), though this 
technology has not been extensively utilized.   
Connecting receptor-mediated signaling to overt brain function is the defining challenge 
of neuropsychopharmacology research. The hypothesis that aberrant neuronal activity 
underlies neuropsychiatric disease combined with the knowledge that drugs modulate 
neuronal activity via receptors has fueled the persistence of this challenge. To date, small 
molecule therapeutics are the first line treatments for debilitating mental illness including 
schizophrenia, Parkinson’s disease, and depression, to name a few. DREADDs offer a unique 
opportunity to study the neurophysiological correlates of therapeutic efficacy due to the 
nature of the DREADD technology and the therapeutic mechanisms of efficacy. First and 
foremost, DREADDs are G-protein coupled receptors – a drug target class of which 36% of 
all currently approved drugs either directly or indirectly modulate (Klabunde and Hessler, 
2002). Furthermore, DREADDs are modulated in a drug-like fashion since the small-
molecule ligand exhibits drug-like properties (Bender et al, 1994; Guettier et al, 2009). 
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Finally, therapeutic efficacy is most often obtained through modulation of diffusely 
expressed albeit specific drug targets (Roth et al, 2004). These three characteristics can only 
be mimicked via the systemic injection of drug and the dispersed expression of the 
DREADD. This similarity to conventional therapeutics may thus facilitate an immediate 
crossover of insights gleaned from research utilizing DREADDs to the physiological 
phenomena responsible and necessary for therapeutic efficacy.  
DREADDs are capable of providing non-invasive temporal control of neuronal 
signaling for three important reasons that clearly distinguish DREADDs from previous 
pharmacosynthetic technology. The first is the two-way selectivity of the receptor-ligand 
pair, in that CNO does not modulate other known effectors in a biological system and that the 
engineered receptor is not activated by effectors present in the biological system. Secondly, 
DREADDs do not exhibit constitutive activity – i.e., in the absence of CNO, the DREADDs 
do not modulate neuronal signaling. The variant rM3Ds has been shown to exhibit 
constitutive activity in pancreatic beta cells (Guettier et al, 2009), though constitutive activity 
has not been observed in striatal neurons (See Section 2.4.1). Finally, the drug used to 
activate the DREADD is bio-available and drug-like, meaning that a simple administration 
method (injection, drinking water, food, etc.) can be used to modulate DREADD activity 
(Bender et al, 1994; Guettier et al, 2009). These advancements are perhaps the most 
important in terms of the ultimate goal of neuropsychopharmacology, as it permits the 






1.2. APPLICATION OF PHARMACOSYNTHETICS 
1.2.1. Selective mimicry of endogenous receptors 
One application is to use pharmacosynthetic constructs as very selective 
pharmacological agents. In this manner, DREADDs can be expressed in a neuronal 
population that matches a pharmacologically intractable endogenous receptor. The Gs-
DREADD validation work in this thesis can be viewed as an example of this type of 
application, in which the DREADD enables selective modulation of a distinct population of 
neurons residing in a nucleus of heterogenous neuronal composition. In this study, the Gs-
DREADD was driven by the adora2A gene in a bacterial artificial chromosome. In the mouse 
genome, the native adora2A gene drives the expression of the adenosine A2A receptor, 
which itself is a Gs-coupled receptor. To date, the availability of selective adenosine A2A 
agonists is limited, and CGS 21680 is the most commonly used. Thus, by mimicking the 
expression of the adenosine A2A receptor with the Gs-DREADD, we essentially created a 
highly selective, spatially restricted adenosine A2A receptor ligand-pair. Utilizing the 
DREADD for selective mimicry is limited, though, in that the DREADD must be of the same 
coupling-type as the endogenous receptor for which it is mimicking. In the instance above, 
the Gs-DREADD and the adenosine A2A receptor both couple to Gs signaling pathways. 
Indeed, the advent of functional selectivity (a.k.a agonist-directed trafficking, biased 
agonism) introduces complications (or potential benefits) that will be discussed in section 
3.3). One can imagine applying pharmacosynthetics in this manner to mimic the effects of 
orphan receptor modulation, where receptors with unique neuronal expression patterns have 
no known modulators.  
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1.2.2. Creating drug-like modulation where none exists 
Additionally, the DREADD system can be conceptualized of as a way to 
pharmacologically modulate spatially defined neuronal populations for which no 
pharmacological modulatory agents exist. Krashes et al. (2011) used DREADDs in this 
fashion to study the arcuate nucleus (ARC) of the hypothalamus. This nucleus has been 
implicated in regulating energy homeostasis and has therefore been a focus of intensive study 
for the understanding and treatment of obesity, with particular focus on agouti-related protein 
(AgRP) neurons expressed in this area. To date, investigative efforts into the function of 
these neurons have been limited to conventional genetic, invasive, and ablative approaches: 
overexpression of AgRP in transgenic mice, central administration of peptides, and ablation 
of AgRP neurons. The first approach removes the temporal specificity required for definitive 
experimentation, whereas the latter approaches introduce confounds associated with non-
reversible and invasive administration techniques. Krashes et al. (2011) utilized DREADD 
technology to study the acute effects of AgRP neuronal activity. The hM3Dq DREADD was 
targeted to AgRP neurons using a Cre-recombinase dependent adeno-associated virus (AAV) 
injected into AgRP-Ires-cre mice. Following i.p. administration of CNO (0.3 mg/kg), 
hM3Dq-expressing mice began feeding and consumed almost four times as much food than 
control mice in the first half hour. Additionally, Krashes et al. infected the same neurons with 
the hM4Di to induce neuronal silencing and observed a decrease in food intake. This study 
demonstrates that DREADDs can be used to introduce pharmacological modulation to nuclei 
for which drug-like compounds do not exist.  
This neuronal circuitry was further explored using virally mediated delivery of 
DREADDS by Atasoy et al. (2012). Although the above study demonstrated that AGRP 
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modulation modulated food intake, the fact that the AGRP neurons project to disparate brain 
nuclei raises the question of which of these downstream nuclei is integral for the ultimate 
behavioral effect of AGRP activation. This was determined through functional-connectivity 
mapping utilizing a combination of optogenetics and phamacosynthetic tools. In this study, 
the hM4Di was used to silence pro-opiomelanocortin (POMC) expressing neurons in the 
arcuate nucleus, a population of neurons modulated by AGRP neurons from within the same 
nucleus, to determine whether inhibition of these neurons modulated food intake. Atasoy et 
al. found that CNO (5.0 mg/kg) administration did not significantly alter food intake over 1 
hour, but repeated treatment (5.0 mg/kg, 3 injections every 8 hours) increased food intake 
over a 24 hour period. The paraventricular hypothalamic (PVH) nucleus also receives AGRP 
innervation, and administration of CNO to mice expressing the hM4Di in these neurons 
caused an increase in food intake. Furthermore, these mice displayed an increase in break 
point during a progressive ratio operant task for food reinforcement, indicating that PVH 
suppression itself can mimic the food seeking and food consumption effects of whole-circuit 
AGRP activation. These experiments were complemented by activating all of the AGRP 
neurons via systemic CNO injection and then selectively silencing the projections to the PVH 
using GABA or NPY antagonists.  Even with activation of brain-wide AGRP neural circuits, 
selective inactivation of these projections caused signifantly reduced food intake. The use of 
pharmacological agents provides a physiological context for the circuitry described in this 
report.    
A similar approach was used to modulate orexin neurons in the lateral hypothalamic 
area. These neurons have been implicated in sleep and wakefulness and produce the 
neuropeptides orexin A and orexin B. As mentioned above, the pharmacological modulation 
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of neuropeptide systems is historically difficult due to issues of invasiveness (local 
microinjection of purified peptide), lack of temporal control (genetic modulation) or off-
target effects (physical ablation). Using virally mediated gene transfer, Sasaki et al. (2011) 
was able to express the hM3Dq and hM4Di in the orexin neurons of the lateral hypothalamic 
area. Following intraperitoneal administration of CNO (5.0 mg/kg) during the light phase 
(when mice typically sleep), the percent of wakefulness during the following hour was 
significantly greater and the NREM time was significantly shorter. Similarly, administration 
of CNO during the dark phase (when mice are typically awake), caused a significant increase 
in wakefulness. Conversely, administration of CNO to mice expressing the hM4Di (the 
inhibitory DREADD) in the orexin neurons decreased wakefulness during the dark phase and 
the light phase.   
Introducing pharmacological modulation to non-druggable neuronal populations was 
also demonstrated by Ray et al. (2011). Here, the hM4Di (referred to as Di in the report) was 
expressed in serotonergic neurons of the brainstem using conditional intersectional genetics.  
In normal mice, an increase in the amount of carbon dioxide inhaled causes an increase in 
breathing. Upon administration of CNO (10 mg/kg), the hM4Di transgenic mice had a 
blunted response to increased CO2 concentrations. These data indicate that the serotonergic 
neurons of the brainstem are involved in the modulation of respiratory activity. Additionally, 
they found that CNO injection decreased oxygen consumption in room air independent of 
ventilation modulation, indicating that these neurons can modulate metabolic rate 
independent of respiration. Furthermore, this group found that modulation of these neurons 
caused long-term changes in body temperature (up to 10 hours in duration), and that this 
effect became desensitized following repeated CNO treatment.  
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1.2.3. Encoding and modulating diffuse neuronal ensembles 
A very elaborate application of pharmacosynthetics was performed by Garner et al. 
(2012) in which the neuronal ensemble encoding a memory trace was captured and recreated 
by DREADDs. To achieve this engram capturing ability, a transgenic mouse was designed to 
express the hM3Dq in active neurons during a conditioning task. This was achieved using a 
c-fos promoter-driven tTa transgenic mouse crossed with the TRE-hM3Dq mouse. The 
protein c-fos is a transcription factor that is upregulated in response to increases in neuronal 
activity. Thus, by using the c-fos promoter sequence, the active neurons of transgenic mice 
are labeled with hM3Dq receptor. These labeled neurons can then be activated via CNO 
administration to re-create the neuronal activity pattern responsible for the initial neuronal 
labeling. Garner et al. used these mice to determine whether a synthetic memory trace could 
be formed and re-created using pharmacosynthetics. To do this, they used a fear conditioning 
protocol in which a mouse is electrically shocked in a novel environment. In this paradigm, a 
mouse learns very quickly that particular environments are associated with an electric shock, 
and when later placed in the shock-paired environment will “freeze” – a well characterized 
behavior associated with learned fear. During these sessions, the neurons involved in the 
formation of these memories will become more active and thus express the hM3Dq. 
Interestingly, they found that the synthetic memory trace encoded by the DREADD-tagging 
could not produce a fear response on its own. The DREADD-encoded memory trace, 
however, was powerful enough to interfere with a naturally encoded memory trace. This 
study exemplifies the ability of pharmacosynthetics to modulate a diffuse but specific 
population of neurons.  
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1.2.4. Long-lasting specific neuronal modulation 
A useful aspect of pharmacological modulation is the duration of activity inherent in the 
pharmacological approach. In addition to the pharmacokinetics of CNO activation, the 
hM3Dq, hM4Di, and rM3Ds have been shown to produce long-lasting neuronal modulation 
exceeding what can be explained by pharmacokinetics alone (see table 1 for summary). This 
longevity of action can be utilized in studies requiring chronic modulation of neuronal 
activity. For example, to determine the influence of neuronal circuit activity on excitatory 
synaptogenesis in medium spiny neurons, Kozorovitskiy et. al (2012) administered a chronic 
regimen of CNO (1.0 mg/kg, twice-daily, from post-natal day 8-15) to mice pups that had 
been infected at post-natal day 0-1 with an AAV carrying a cre-dependent hM4D. In this 
study, D1 and D2-Cre mice were used to target expression of the hM4Di in the two primary 
neuron populations of the striatum. The chronic regimen of CNO administration, theorized to 
produce long-lasting neuronal activity modulation, dampened the synaptogenesis of direct or 
indirect pathway MSNs as measured by mEPSC frequency and spine density on day 15 in 
mice expressing hM4Di throughout the striatum. In mice expressing the hM4Di unilaterally 
in a more dispersed manner (theorized to not effect circuitry activity), there was no effect of 
CNO on synaptogenesis. To determine whether the corticostriatal neurons (those that project 
to the striatum from the cortex) could influence synaptogenesis, the hM4D AAV was injected 
to the Rbp4-cre mouse, a mouse expressing Cre in corticostriatal neurons. These mice were 
treated with the same chronic regimen of CNO. On day 15, decreased mEPSC frequency and 
spine density was observed, indicating a decrease in synaptogenesis. Similar results were also 
observed when measured at postnatal day 25-28, indicating these changes persist into 
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adulthood. This study demonstrates the ability of the pharmacosynthetic approach to provide 
chronic neuronal modulation.  
 
1.3. CONSIDERATIONS AND IMPLICATIONS OF THE PHARMACOSYNTHETIC 
APPROACH 
Pharmacosynthesis requires a consideration of many factors to be effectively utilized. 
The key elements to be considered are the expression of DREADD and the dose of CNO 
required for experimental manipulation. Here I provide a primer on the consideration of these 
elements.  
1.3.1. Expression systems 
The primary challenge in pharmacosynthetics is inserting the DREADD receptor into 
the desired tissue of the model organism. To date, this has been achieved using virally 
mediated gene transfer and the genomic insertion of a transgene. Although a full review of 
each approach is beyond the scope of this dissertation, the benefits and complications of each 
approach will be briefly discussed.  
1.3.1.1. Virally Mediated Gene Transfer 
Virally mediated gene transfer utilizes viral mechanisms to insert the DREADD DNA 
into a neuronal population. There are many different types of viruses available, each having 
their own benefits and drawbacks. The reader is directed to reviews and applications of viral 
vectors and their utility (de Silva and Bowers, 2011; Foust et al, 2009; Teschemacher et al, 
2005; Weinberg et al, 2012; Wu et al, 2006). The primary benefit of the viral approach is the 
relatively quick turnaround between project conception and functional animal model 
expressing the DREADD. In addition to the expediency provided by this approach, the local 
microinjection of viral particles enhances the spatial specificity of DREADD expression. 
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Finally, the viral approach permits utilization of the DREADD in model organisms for which 
transgenic approaches are not available or widespread (e.g., rats, monkeys).  The drawbacks 
of the viral approach arise from the nature of local microinjections and the size limitations of 
viral packaging. This vector delivery method is invasive, potentially inducing an immune 
response and causing damage to tissue, including cell populations either directly or indirectly 
involved in the scrutinized output. Additionally, the spatial resolution provided can also be a 
limitation, in that DREADD expression is limited to the number of microinjection sites and 
the spread of viral particles. This latter point, however, can be a benefit depending on the 
goals of the study. Furthermore, the expression pattern of DREADDs between animal 
subjects will not be precisely identical due to differential stereotactic coordinate alignment, 
inconsistent viral diffusion, and experimental variation. Finally, viruses are only capable of 
carrying a certain quantity of DNA, potentially limiting the addition of desirable vector traits 
including targeting information (promoter sequences) and cell-type markers (fluorescent 
proteins).  
1.3.1.2. Genomic Insertion of Transgene 
Genomic insertion of a DREADD-encoding transgene involves the creation of a new 
line of genetically modified mice or the selective breeding of extant transgenic lines. The 
benefits of the transgenic approach are inherent to genome-level insertion of a transgene. 
First and foremost, the transgenic line of mice carries the transgene and expresses the 
DREADD in accordance to the genetic information in the transgene. Thus, no invasive 
interventions are necessary to obtain DREADD expression, providing a truly non-invasive 
means of cell-type specific signaling. Secondly, DREADDs can be expressed in a more 
dispersed manner using a transgenic approach. Whereas virally mediated gene transfer can 
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only provide expression of the DREADD in the area of viral diffusion, the transgene inserted 
into the genome is present in all cells. Expression of the DREADD is dependent upon the 
information contained in the transgene, and while the genetic sequences that confer cell-type 
specificity of expression are still a matter of research, certain promoter sequences have been 
determined. Thus, while the noninvasive component is definitively beneficial, the utility of 
dispersed expression patterns is dependent upon the research goals.  
One type of transgenic approach is to create a new transgenic line to suit the needs of 
the intended research. When creating a new line of DREADD transgenic mice, the 
DREADD-encoding construct is inserted downstream of a promoter that is useful for the 
research goal. For instance, the Gs-DREADD mice described above utilized the adenosine 
A2A receptor bacterial artificial chromosome (BAC) to drive DREADD expression in 
striatopallidal medium spiny neurons, an area where the adenosine A2A receptor is naturally 
enriched. This permitted the selective activation of Gs signaling in those neurons in mice 
carrying a single transgene. One benefit of the single transgene approach is breeding 
efficiency: hemizygous breeding strategies can produce 50% transmission with the end result 
being 50% of the litter can be used for study. Additionally, because cell-type specificity is 
transmitted in one transgene, these mice can be easily crossbred with other types of 
engineered mice. The downside of this approach is that these single-transgene mice can only 
be used to study the cell population originally intended. An additional downside is that 
efforts to identify the genetic information responsible for tissue targeting have been, for the 
most part, unsuccessful, though a select few promoters have been commonly used in 
neuroscience research. One way to overcome this lack of knowledge is to knock-in the 
transgene, such that the endogenous promoter for a given neuronal subtype carries the 
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DREADD sequence in addition to the endogenous gene product. To avoid interfering with a 
particular genomic locus, an alternative transgenic strategy is to create a transgene containing 
the entirety of the genetic information associated with a particular cell-type specific protein. 
This approach can be achieved by using bacterial artificial chromosomes, which are capable 
of carrying 200-300 kb of genetic information, a drastically larger amount than other 
transgenic approaches utilize (Heintz, 2001). For instance, the camKII-alpha promoter 
sequence is 8.5 kb (Tsien et al, 1996), whereas the adora2A BAC is 175 kb. Finally, creating 
a transgenic mouse is both resource intensive and the effort has no guaranteed yield, 
depending on the strategy.  
Alternatively, targeting DREADD expression to a cell type of interest can be achieved 
using conditional intersectional genetics. This approach involves the selective breeding of 
extant transgenic lines to produce mice carrying multiple transgenes; i.e., polytransgenic 
mice. In these mice, the expression specificity of the DREADD depends on the design of the 
transgenes, an approach called “intersectional genetics”. A handful of technologies are 
available for this approach though the number of transgenic mice carrying these technologies 
is ever expanding. Prominently in use are the Cre, Flp, and Tet technologies, all of which are 
based on proteins and DNA sequences exogenous to the targeted model organism (in this 
case, the mouse) (Mallo, 2006). The Cre and Flp systems are based on the recombinases and 
their associated DNA targeting sequences. In these systems, one mouse carries a transgene 
for the Cre or FLP protein in which the protein sequence is downstream of a promoter that 
drives expression in a particular cell population (cell population A). A second mouse has a 
separate transgene, in which the DREADD sequence is inserted downstream of a ubiquitous 
promoter followed by a stop cassette that is flanked by either the Cre excision sites (LoxP) or 
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the Flp excision site (Flpe). Thus, in the cell population that expresses Cre or Flp, the stop 
cassette is removed from the genetic sequence. The nuclear expression machinery can then 
translate the DREADD sequence into protein in that cell population. In the cells that do not 
express Cre or Flp, the DREADD transgene remains silent due to the presence of the stop 
cassette. The Cre / Flp systems can also take advantage of a second phenomenon of the 
recombinatorial proteins in that they can reverse the direction of the sequence between the 
excision sequences. Dependent upon the orientation of the excision sequences, the Cre and 
Flp can either excise the bookended DNA or flip the direction (Atasoy et al, 2008). The 
“reversal” approach is less leaky than the excision method; i.e., the intended specificity of 
expression is more likely to occur.  
In the Tet system (Kistner et al, 1996), one mouse is designed with a transgene 
containing the tet trans-activator (Tta) sequence downstream of a cell-type specific promoter. 
A second mouse is designed with a transgene containing the DREADD sequence 
downstream of the tet-response element (TRE) sequence. When the two mice are interbred to 
create double-transgenic offspring, the tet trans activator binds to the tet response element 
and permits DREADD expression. This system also permits for temporal control by the 
administration of doxycycline to the organism. Doxycycline binds to the trans activator and 
blocks its interaction with the tet response element, ultimately inhibiting expression of the 
DREADD. Alternatively, the reverse trans activator (rTta) can be used, in which doxycycline 
administration is necessary for the interaction of the trans activator and the response element. 
In this version of the system, doxycycline can be administered to induce the expression of the 
DREADD. The tet system has been enhanced recently with the tet-on 3G system (Fan et al, 
2012), but the underlying principles remain.  
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1.3.1.3. Combinatorial approaches 
Already the world of neuroscience research is seeing the full implementation of these 
technologies and the benefits of combining them. For example, the Krashes et al. (2011) and 
Sasaki et al. (2011) studies combined the specificity of expression provided by the genomic 
transgene approach with the spatial resolution and quick turnaround of the viral approach to 
achieve cell-type specific neuronal modulation. The Ray et al. (2011) study used 
intersectional genetics, combining Cre and Flp recombination to increase the specificity of 
DREADD expression with minimal invasiveness. At this point, the ability to target 
DREADD expression to specific tissue populations depends on the transgenic state of the art.  
1.3.2.  CNO Doses and Routes of Administration 
In the articles mentioned above, a range of CNO doses is used to obtain effects at the 
whole-organism level, and these doses are summarized in Table 1. The dose of CNO required 
varies depending on the expression system, localization of expression and type of DREADD. 
For example, the hM3Dq DREADD is very effective at depolarizing neurons, and thus, 
relatively low doses can be used to elicit an effective neuronal response (Alexander et al, 
2009) . On the other hand, the hM4Di is reportedly less effective at inhibiting neuronal firing, 
so higher doses of CNO are occasionally used (Ray et al, 2011; Sasaki et al, 2011). Beyond 
the inherent differences between Gq and Gi modulation of neuronal excitability, the effects 
of the CNO-DREADD mediated manipulation depend on the tissue distribution of the 
DREADD. For example, the hM3Dq mice originally characterized express the Gq DREADD 
in all neurons of the cerebrum using the calmodulin II kinase alpha promoter, creating a 
condition in which low doses of CNO could influence neuronal activity on a large scale 
(Alexander et al, 2009). Conversely, the transgenic mice used in Garner (2012) used the c-
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fos promoter to drive expression of the hM3Dq, so the DREADD was expressed at lower 
levels and higher doses of CNO were apparently necessary. Furthermore, Krashes (2011) 
used a viral approach to express the hM3Dq in a small nucleus and administered 5.0 mg/kg 
CNO to elicit a response in these mice. From the body of work performed with DREADDs to 
date, it can be seen that the dose of CNO is variable and dependent on the type of DREADD 
and the expression system used.  
To date, a majority of studies performed have used the intraperitoneal route of 
administration, though other routes of administration are possible. Our lab has demonstrated 
that CNO can be administered through the drinking water to create chronic administration 
conditions (10 mg/kg/day, unpublished observations).   
1.4. LIMITATIONS OF CURRENT PHARMACOSYNTHETIC TECHNOLOGY 
1.4.1. Pharmacological vs. Physiological Manipulation 
Pharmacosynthetic modulation of neuronal signaling differs from physiological 
modulation of neuronal signaling that exists within the brain. Firstly, the drug-like 
modulation of receptor-mediated signaling is qualitatively different than the endogenous 
neurotransmitter modulation of receptor-mediated signaling. Whereas administration of a 
drug causes a uniform modulation of all available receptors simultaneously and with 
relatively similar concentrations, neurotransmitter modulation is dependent on the activity of 
neurons. These different types of modulation can be discribed as wiring transmission and 
volume transmission (Agnati et al, 2010). Pharmacological, and therefore 
pharmacosynthetic, modulation is akin to volume transmission. Neurons release 
neurotransmitter in a phasic, bursting nature, creating waves of neurotransmitters in the 
synaptic cleft to influence wiring transmission while simultaneously creating a tonic level of 
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modulation due to synaptic leakage to potentiall influence volume transmission (Goto et al, 
2007). This phasic nature of ligand-induced signaling can not be replicated using 
pharmacosynthetics due to the uniform distribution of a pharmacological agent. Furthermore, 
the site of action of a neurotransmitter is mostly restricted to the synapse, though extra-
synaptic receptors are present. This differential localization of endogenous receptor creates 
the possibility for differential response to neurotransmitter presence, based on the “leakage” 
from the synapse. This differential response will not be observed in a pharmacosynthetic 
system due to the uniform distribution of ligand. For these reasons, pharmacosynthetic tools 
are best utilized to study a pharmacological response of a system as opposed to the 
physiology of the system itself.  
1.4.2. Limitations of Technology 
To date, the primary consideration in the design of pharmacosynthetic tools has been 
the control of specific signaling types: G protein signaling pathways or ion conductances. 
Beyond the signaling types afforded by these receptors, there are other aspects of receptor 
proteins that ultimately influence the effects of receptor signaling. Firstly, the differential 
localization of a receptor can influence the effect of drug modulation. For instance, synaptic 
GPCR signaling can have differential effects than extrasynaptic GPCR signaling (Fuxe et al, 
2012). To date, the targeting of DREADDs to specific cellular compartments is dependent on 
the targeting and trafficking information contained within the protein sequence of the 
muscarinic receptor, the endogenous receptor from which the DREADD was engineered. 
Studies into the localization of the muscarinic receptors are still underway, though it is 
known that the muscarinic M3 receptor is found in spiny dendrites and axon terminals 
(Nathanson, 2008). Furthermore, the targeting of the receptor construct validated in my 
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research (rM3Ds) is influenced by the presence of the turkey beta1 adrenergic receptor loops. 
Therefore, the targeting of the rM3Ds could be influenced by the trafficking information of 
both the muscarinic M3 receptor and the beta1 adrenergic receptor. The current targeting and 
trafficking information encoded by the available DREADDs represents the state-of-the art 
and is an area requiring further development to enhance the capabilities of pharmacosynthetic 
technology.  
1.5. CONCLUSIONS 
1.5.1. Key Differences Between Optogenetics and Pharmacosynthetics  
It is important to note the differences between the pharmacosynthetic approach and the 
optogenetic approach. Using optogenetics, one can gain precise spatio-temporal control of 
neuronal firing using a combination of light and transgenic expression of engineered 
receptors. Among the optogenetic tools available, one difference is the level of invasiveness 
required for experimental manipulation when compared to pharmacosynthetics. Using 
optogenetics, one must deliver light to neurons- a process that currently requires implantation 
of fiber optics into the brain. Notwithstanding the proper implementation of control 
conditions, experiments can be imagined for which survival surgeries (and the subsequent 
hardware attachment) present insurmountable confounds. In its most noninvasive form - 
genomic transgene – pharmacosynthetic manipulation can be achieved with minimal 
invasiveness to the organism using peripheral administration of CNO (or even via food or 
drinking water). However, the prevalent use of virally mediated gene transfer in 
pharmacosynthetics (Table 1) would indicate that the level of initial invasiveness between 
approaches is similar.  A second difference is the type of neuronal modulation afforded. 
Currently, the most widespread variation of optogenetics utilizes the channelrhodopsins, a 
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family of light activated ion channels that directly modulate the ion conductance of neuronal 
membranes and either hyperpolarize or depolarize neurons. In contrast, DREADDs modulate 
G-protein mediated signaling – signaling cascades for which neuronal hyperpolarization or 
depolarization are only one outcome. However, there are optogenetic tools available – the 
OptoXRs - that modulate G-protein mediated signaling using light, though these have not 
gained widespread use.  
Whereas the type of signaling afforded by these two approaches is not considerably 
different, nor the level of invasiveness considering the use of viral-mediated gene transfer, it 
can be argued that the nature of the neuronal modulation provided by these two technologies 
is what clearly separates them as distinct experimental tools with considerably different 
utility. The nature of the neuronal modulation created using pharmacosynthetics more closely 
resembles the hormonal signaling mechanisms found in the brain, in that the modulatory 
agent (CNO) “lingers” in the extraneuronal space and activates signal transduction 
mechanisms (GPCRs) dependent on diffusion, clearance, and receptor regulatory 
mechanisms (internalization, desensitization). This nature of activity more closely resembles 
the nature of metabotropic neurotransmitter or drug activity than any other process. On the 
other hand, optogenetics more closely resembles the electrochemical functionality of 
neurons. That is, the manipulation of membrane conductance more closely resembles the end 
result of factor-induced neuronal changes. In other words, pharmacosynthetics permits for 
the study of neuronal modulation itself, whereas optogenetics permits for the study of what a 
modulated neuron actually does in the brain. While these differences should fundamentally 
affect the type of experimentation performed with the respective technologies, 
pharmacosynthetics has yet to be fully implemented in this fashion.  
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1.5.2. Concluding remarks  
Pharmacosynthetics provides an effective means to study the physiological effects of 
artificial, drug-like modulation of distinct neuronal populations. The specificity and 
exclusivity of GPCR modulation afforded by the technology can be utilized to explore 
mechanisms of therapeutic efficacy to further the development of small-molecule 
therapeutics. Further development of pharmacosynthetics will create levels of experimental 
manipulation that will challenge our conventional understanding of signal transduction and 
pharmacology.  With this reimagination of this technology, it can be seen that the 
pharmacosynthetic approach provides unprecedented ability to truly answer the defining 
question of neuropharmacology – how do drugs modulate brain activity?   
 
CHAPTER 2. NEURONAL VALIDATION OF GS COUPLED DREADD (RM3DS)  
2.1. INTRODUCTION 
Circuits of the basal ganglia, a brain region responsible for voluntary behavior and 
reward, are implicated in a variety of neuropsychiatric disorders including Parkinson’s 
disease, Huntington’s disease, Obsessive Compulsive Disorder, and addiction. A more 
thorough understanding of the signaling circuits that modulate basal ganglia function could 
lead to the development of better therapeutics for these disorders. The ability to exclusively 
modulate the intracellular signaling pathways of distinct circuits in vivo would be an 
extremely useful tool to facilitate studies investigating how circuits function in the brain. To 
this end, the Roth laboratory has recently created and validated a family of designer G 
protein-coupled receptors (GPCRs) that facilitate exclusive modulation of G protein 
signaling pathways. A family of Designer Receptors Exclusively Activated by Designer Drug 
(DREADDs) was developed such that the receptors (1) are not activated by their native 
ligand, acetylcholine; (2) lack any detectable intrinsic activity; and (3) are selectively 
activated by the bioavailable, inert synthetic ligand, clozapine-N-oxide (CNO), a metabolite 
of clozapine. By coupling DREADD technology with a transgenic approach to target 
DREADD expression to a specific subpopulation of neurons, it may be possible to achieve 
exclusive modulation of intracellular signaling pathways in distinct circuits in vivo. This 
proposal investigates the hypothesis that the Gαs DREADD, expressed in a specific cell type, 
allows for the spatiotemporal control of Gαs signaling in distinct circuits in vivo, and further 
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tests the utility of DREADDs in interrogating the relationship between intracellular signaling 
in specific neuronal circuits and behavior. This enabling technology has the potential to 
provide neuroscientists an innovative research strategy (pharmacological control of cell type-
specific signaling with unprecedented precision) to advance towards Strategic Objective 1 of 
the National Institute of Mental Health (promote discovery in the brain and behavioral 
sciences to fuel research on the causes of mental disorders). Ultimately, the knowledge 
obtained could yield new insights into basal ganglia function.  
 
2.2. THE STRIATUM AS AN IDEAL REGION FOR TESTING SELECTIVE 
CONTROL OF NEURONAL SIGNALING IN DEFINED NEURONAL 
POPULATIONS. 
Cell-type specific control of neuronal signaling can provide valuable insight into the 
neuronal correlates of behavior, disease, and mechanisms of therapeutic efficacy. Medium 
spiny neurons (MSNs) are the projection neurons of the striatum and are segregated into two 
populations defined by their efferent projections and their neuropeptide and receptor 
expression profiles. Striatonigral MSNs project to the substantia nigra and express dynorphin 
and substance P neuropeptides, in addition to being enriched in D1-dopamine receptors. 
Striatopallidal MSNs project to the globus pallidus, express enkephalin and are enriched in 
D2-dopamine and A2A-adenosine receptors (Ferre et al, 1992; Gerfen et al, 1990; 
Svenningsson et al, 1998). The activation of striatopallidal neurons is thought to produce an 
inhibitory effect on motor behavior (DeLong, 1990; Kravitz et al, 2010), and these D2-
dopamine receptor containing neurons have been implicated in both the etiology and 
potential therapy of many neuropsychiatric diseases (Beaulieu and Gainetdinov, 2011; 
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Emilien et al, 1999). The distinctive functional and biochemical composition of these 
neurons present a suitable region to validate the ability of the DREADDs to selectively 
control cell type specific neuronal signaling.  
The Gαs- and Gαi- G protein signaling cascades, modulated by D1- and D2-receptors, 
respectively, are implicated in both the short-term excitability and the long-term plasticity of 
MSNs (Centonze et al, 2001; Surmeier et al, 2007). Striatal G protein signaling cascades 
have primarily been studied as a consequence of activating dopamine receptors, but 
activation of Gαs signaling downstream of other GPCRs also has significant effects. For 
example, striatopallidal Gαs signaling modulated by the A2A-adenosine receptor influences 
psychostimulant activity (Brown and Short, 2008). To create a mouse model in which the 
cellular and behavioral consequences of striatopallidal-specific Gs-type signaling (G protein 
signaling that increases cAMP production) can be studied, we took advantage of technology 
we developed whereby evolved GPCRs (DREADDs, or Designer Receptor Exclusively 
Activated by Designer Drug) are expressed in a cell-type-specific fashion to remotely control 
cellular signaling (Armbruster et al, 2007). 
In prior work, the ability of the rM3Ds DREADD to remotely control Gs signaling in an 
inducible and cell-type specific fashion was demonstrated by transgenic expression of rM3Ds 
in pancreatic -cells (Guettier et al, 2009). Here, I validate the rM3Ds in a neuronal context 
in vivo by creating a bacterial artificial chromosome (BAC) transgenic mouse line carrying 
the Gs-DREADD (rM3Ds) downstream of the adora2A (adenosine A2A receptor) promoter. 
Adora2A-rM3Ds transgenic mice afford a unique pharmacosynthetic means to specifically 
modulate Gαs/olf signaling in vivo in a spatially and temporally-controlled fashion using the 
pharmacologically inert, designer drug clozapine N-oxide (CNO; see (Armbruster et al, 
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2007)). Herein, I use this novel transgenic line to validate the rM3Ds by measuring the 
biochemical, electrophysiological, and behavioral consequences of CNO administration to 
adora2A-rM3Ds transgenic mice.  
2.3. METHODS 
Plasmids: The plasmid map of the p-rM3Ds-IRESmCherry construct is detailed in 
Figure 2.  
Drugs: Clozapine N-oxide (CNO) was obtained from the NIH as part of a Rapid Access 
to Investigative Drug Program funded by the National Institute of Neurological Disorders 
and Stroke (NINDS). D-amphetamine (AMPH) and isoproterenol were purchased from 
Sigma (St. Louis, MO). For experiments in mice, CNO was first dissolved in DMSO then 
brought to final concentration with 0.9% saline and a final concentration of DMSO of 0.5%.  
Amphetamine was dissolved directly into 0.9% saline. For all experiments, the appropriate 
(e.g., 0.9% saline for amphetamine experiments and 0.5% DMSO in saline for CNO 
experiments) vehicle controls were utilized. Unless otherwise noted, the dose of CNO was 
1.0 mg/kg and the dose of amphetamine was 2.0 mg/kg. Drugs were injected 
intraperitoneally (i.p.) at a volume 100 ul /10 g body weight. For in vitro studies, drugs were 
dissolved in DMSO at 10 mM as stocks and then diluted into sample buffer.  
In vitro studies - cAMP accumulation in neurons: The IRES sequence was cloned from 
the pIRES-neo vector (Clontech, Palo Alto, CA) into an mCherry vector (Shu et al, 2006) 
using the Xi-clone High-Speed Cloning Kit (Gene Therapy Systems, Inc., San Diego, CA) to 
generate pIRES-mCherry by Ying Pei. The coding region for rM3Ds was subsequently 
subcloned by Ying Pei into pIRES-mCherry upstream of the IRES sequence to generate p-
rM3Ds-IRESmCherry. 
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Lentiviral studies were done as previously described with modification (Abbas et al, 
2009; Alexander et al, 2009) by Ying Pei. To generate a lentiviral construct, the coding 
region for rM3Ds-IRESmCherry was subcloned into the lentiviral expression vector FUGW 
(Lois et al, 2002), a gift from Dr. Guoping Feng (Duke University). Fugene6 (Roche Applied 
Science, Indianapolis, IN) was used to co-transfect seven 150 cm
2
 dishes of HEK293T cells 
with the FUGW plasmid and two viral packaging constructs (Δ8.9 HIV-1 and VSVG) in a 
ratio of 3.3:2.5:1. Lentivirus-containing media was collected 48 hours post-transfection. 
Virus was concentrated by centrifugation and Amicon ultra-15 centrifugal filter devices 
(Millipore, St. Louis, MO), aliquoted, and frozen at -80°C until use.  Rat cortical neurons 
were infected with FUGW-rM3Ds-IRES-mCherry as previously described (Alexander et al, 
2009). Two days following infection, cells were exposed to increasing concentrations of 
CNO, and cAMP accumulation was quantified using the Catchpoint assay per manufacturer’s 
instructions (Molecular Devices).   
Assessment of cAMP production in HEK293T cells: Agonist-induced cAMP production 
was measured in living cells as described previously (Abbas et al, 2009; Kimple et al, 2009) 
by Vincent Setola. HEK293T cells were maintained in DMEM with L-glutamine, 1 g/l 
glucose, 10% fetal bovine serum (all from Cellgro) (C/H medium). The day before 
transfection, the cells were seeded in 10-cm dishes (Greiner) in C/H medium (4 million 
cells/plate). The next day, cells were transfected (using the calcium phosphate method) with 
2 μg of the pGloSensor-22F cAMP biosensor (Promega) and various amounts of expression 
vectors for the Gα subunits and the hM3/turkey beta1AR chimer DREADD (rM3Ds) at the 
indicated ratios. Empty pcDNA3.1(+) was used as an inert vector so that each plate was 
transfected with similar amounts of DNA (12 μg). The next day, the cells were harvested 
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with dilute trypsin, resuspended in 1X HBSS (with calcium and magnesium) (Invitrogen) 
supplemented with 20 mM HEPES, pH 7.4 (drug buffer), counted, and diluted to 15,000 
cells/20 microliters. The cell suspension was added to white 384-well plates (Greiner) (20 
microliters/well). After a 1-2 hr incubation, the cells were challenged with 10 
microliters/well of 3X working dilutions of CNO (for concentration-dependent activation of 
rM3Ds) or isoproterenol (for concentration-dependent activation of endogenously expressed 
beta2AR). The 3X working dilutions were prepared in drug buffer containing 6% (i.e., 3X) 
GloSensor reagent (Promega). Ten minutes after agonist challenge, the luminescence was 
counted (1 s/well) on a TriLux (Perkin Elmer) microbeta/luminescence plate reader. For each 
transfection condition (rM3Ds +/- Gα), the luminescence per well was expressed as a 
function of the log [agonist], and the data were fit using a three-parameter logistic equation 
as described previously (Alexander et al, 2009). Best-fit pEC50 and Emax values +/- SE 
were compared across transfection conditions and between agonists. 
Animal Subjects: Behavioral, biochemical, and electrophysiology experiments were 
performed at the University of North Carolina and Duke University in accordance with the 
National Institutes of Health’s guidelines for the care and use of animals and with approved 
animal protocols from the Institutional Animal Care and Use Committees of the 
aforementioned institutions.  
Generation of adora2A-rM3Ds mice: Transgenic mice were created by the Duke 
Neurotransgenic Core (Durham, NC) using standard techniques previously described (Gong 
et al, 2003). The rM3Ds-IRES-mCherry construct was recombineered into the adenosine2A 
bacterial artificial chromosome (BAC; GENSAT1-BX868, BAC address: RP24-238K3) 
downstream of the endogenous ATG codon, and this adora2A-rM3Ds-IRES-mCherry BAC 
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was then injected into the pronucleus of B6SJLF1/J mouse oocytes. Genotyping was 
performed by PCR of genomic DNA extracted from tail clips using the following primers for 
mCherry: FW 5´-GTGAGCAAGGGCGAGGAGG-3´ REV: 5´-
GTCGGCGGGGTGCTTCAC-3´ using the following cycle: Initial denaturation: 94 – 4 
minutes, followed by 30 cycles of 94°C 30s / 65°C 30s / 72°C 30s, followed by 72°C 4 
minute final extension. PCR products were analyzed using gel electrophoresis (1%, Aqua Por 
LE, National Diagnostic, Atlanta, GA), and rM3Ds positive mouse samples present a clear 
band at 200 bp (Figure 2d). From this screen, 9 genotype-positive mice were found. These 
mice were bred to wild-type (C57BL/6J) mice, and their offspring were screened for 
mCherry expression via immunohistochemistry for mCherry following the methods detailed 
below. Three mCherry-positive founder lines were identified and named AD6, AD8, and 
AD10. The AD6 line was used in the present study. Following initial screening, AD6 mice 
were bred onto the C57BL/6J background. The breeding strategy had consistent pairing with 
an AD6 mouse always paired with a C57BL/6J mouse; thus, all mice used in these studies 
were hemizygous for the adora2A-rM3Ds gene. The AD6 line of mice is referred to as 
adora2A-rM3Ds mice in this manuscript. Mice used for behavioral studies were bred in large 
cohorts using a harem-breeding strategy, and littermate pairings between conditions were 
used. All behavioral studies were performed on mice of the F3 generation or later. The 
amphetamine behavioral sensitization studies and behavior core screen were performed on 
the F3 generation. Electrophysiology studies were performed on the F6 generation or later.  
Other lines of mice used: Drd1a-EGFP (000297-MU) and Drd2-EGFP (000230-UNC) 
reporter mice were obtained from the Mutant Mouse Regional Resource Centers and crossed 
with adora2A-rM3Ds mice for quantification of expression of rM3Ds in D1 and D2-
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expressing neurons. C57BL/6J mice were obtained from Jackson laboratories (Bar Harbor, 
ME).  
Immunohistochemistry and image analysis: Mice were anaesthetized with 
tribromoethanol (Avertin) and then transcardially perfused with 20 ml PBS (137 mM NaCl, 
2.7 mM KCl, 8.1 mM Na2HPO4, 2 mM KH2PO4, pH 7.5) followed by 40 ml 4% 
paraformaldehyde (PFA) in PBS. Brains were removed and placed in 4% PFA overnight at 
4°C gentle rocking. The following day, brains were placed in 30% sucrose PBS solution and 
continued to rock at 4°C. On day 3, when brains had sunk to the bottom of the tube, the 
brains were frozen on dry ice. Sections were obtained using a cryostat at 30 μm. Slices were 
processed either thaw-mounted to the slides or in a free-floating fashion. Samples were 
initially incubated in 0.5% TritonX-100 in PBS for 30 minutes RT, followed by a 30 minute 
incubation in blocking buffer (3% BSA 0.5% TritonX-100 in PBS) at RT. Samples were then 
incubated with primary antibodies overnight at 4°C in blocking buffer. The following day, 
samples were washed 4 X 10 with PBS 0.5% TritonX-100, followed by 1 hour RT incubation 
with secondary fluorescent-conjugated antibodies in blocking buffer. Primary antibodies 
used: anti-RFP, ab65856, 1:1000, AbCam, Cambridge, MA; Anti-GFP, A11122, 1:1000, 
Invitrogen, Carlsbad, CA. Secondary antibodies used: goat anti-rabbit AlexaFluor-488 and 
goat anti-mouse AlexaFluor-594 antisera (1:250, Invitrogen, Carlsbad, CA).  Hoechst stain 
was added to secondary incubation at 1:2000 for some experiments. Fluorescent images were 
collected on a Nikon 80i Research Upright Microscope (Nikon, Tokyo, Japan) equipped with 
Surveyor Software with TurboScan (Objective Imaging, Kansasville, WI). Tiled images were 
collected with a Qimaging Retiga-EXi camera (Qimaging, Surrey, BC, Canada). For 
colocalization studies, images of coronal slices were analyzed using ImageJ software (NIH). 
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A region of interest in the body of the striatum was selected for N=3 mice, and the number of 
EGFP positive and mCherry positive cell bodies was quantified. 
DARPP-32 study: Mice were injected i.p. with CNO (5.0 mg/kg), cocaine (20.0 mg/kg) 
or vehicle and then sacrificed 15 min later by cervical dislocation. The ventral striatum was 
isolated using a rapid head-freeze dissection technique as described previously (Beaulieu et 
al, 2004). Frozen tissue samples were probe sonicated in 95°C 1% SDS buffer containing 1X 
Halt phosphatase inhibitor (Halt, Pierce, 87786) and 1X protease inhibitor (Roche 
Diagnostics, Complete, no. 11697498001). Protein concentration of sample was determined 
using the BCA method (Pierce). Samples were boiled in Laemmli buffer, and 25 ug of 
protein were loaded into 10% SDS-PAGE gels, transferred onto nitrocellulose membranes, 
and incubated with antibodies to pT34 DARPP-32 (Phosphosolutions, Aurora, CO, p1025-
34, 1:300, TBST / 3% BSA), total DARPP-32 (BD Transduction, San Diego, CA, 611520, 
1:1500, TBST / 5% BSA), pERK1/2 (Cell Signaling, Danvers, MA, 9101, 1:500, TBST / 5% 
milk), total ERK1/2 (9107, 1:500, TBST / 5% milk), pAKT308 (2965, 1:100, TBST / 5% 
BSA), or total AKT (2920, 1:1500, TBST / 5% BSA). Blots were imaged on the LI-COR 
Odyssey instrument (LI-COR Biosciences, Lincoln, NE). The phospho-specific probe band 
intensity was measured using NIH ImageJ software and was normalized to total probe band 
intensity. The fold stimulation was determined by normalizing these values to the average of 
the vehicle treatment group.  
Behavioral Phenotype of adora2A-rM3Ds mice: Twelve littermate pairs (7 male pairs, 5 
female pairs) of adora2A-rM3Ds transgenic (rM3Ds) mice and wild-type (WT) mice 
underwent a broad survey of behavioral testing. Mice were approximately three months old 
when testing began. Procedures were conducted by an experimenter blind to mouse 
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genotype.  Data were analyzed using one-way or repeated measures Analysis of Variance 
(ANOVA) to determine effects of genotype.  Fisher's protected least-significant difference 
(PLSD) tests were used for comparing group means only when a significant F value was 
determined in the overall ANOVA.  Within-genotype comparisons were conducted to 
determine side preference in the social approach test, and quadrant preference in the water 
maze.  For all comparisons, significance was set at p < 0.05. 
Testing Regimen: Mice were tested in the following procedures, with at least one or two 
days between each assay: elevated plus maze test for anxiety-like behavior, neurobehavioral 
screen, activity in an open field, accelerating rotarod (2 tests, 48 hours apart), social approach 
test, acoustic startle test, buried food test for olfactory ability, visual cue test in the Morris 
water maze, hidden platform test for spatial learning, reversal learning in the Morris water 
maze, hotplate test for thermal sensitivity. 
Elevated plus-maze test: Mice were given one 5-min trial on a metal plus-maze, which 
had two closed arms, with walls 20 cm in height, and two open arms.  The maze was elevated 
50 cm from the floor, and the arms were 30 cm long.  Animals were placed on the center 
section (8 cm x 8 cm), and allowed to freely explore the maze.  Arm entries were defined as 
all four paws entering an arm.  Entries and time in each arm were recorded during the trial by 
a human observer via computer coding.  Percent open arm time was calculated as 100 x (time 
spent on the open arms/time in the open arms + time in the closed arms).  Percent open arm 
entries was calculated using the same formula. 
Neurobehavioral screen for reflex, sensory, and motor impairment: The 
neurobehavioral screen consisted of several measures to assay overall appearance and 
behavior of the mice.  Measures included general observations on coat condition, body 
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posture, and normality of gait.  Normal reflexive reactions to a gentle touch from a cotton-
tipped swab to the whiskers on each side of the face, and the approach of the swab to the 
eyes, were assessed.  Each subject was placed in a small, empty plastic cage, and ability to 
remain upright when the cage was moved from side-to-side or up-and-down was noted.  
Locomotor coordination was assayed by allowing the mouse to walk across an elevated 
dowel (wrapped in nylon rope to facilitate grasping) and to climb down a similar pole.  Each 
subject was also placed on a wire grid and allowed to hang for one minute.  Reaction to 20 
seconds of tail-suspension was recorded. 
Buried food test for olfactory function: Several days before the olfactory test, an 
unfamiliar food (Froot Loops, Kellogg Co., Battle Creek, MI) was placed overnight in the 
home cages of the subject mice.  Observations of consumption were taken to ensure that the 
novel food was palatable to the mice.  Sixteen to twenty hours before the test, all food was 
removed from the home cage.  On the day of the test, each mouse was placed in a large, clean 
tub cage (46 cm L x 23.5 cm W x 20 cm H), containing paper chip bedding (3 cm deep), and 
allowed to explore for five minutes.  The animal was removed from the cage, and one Froot 
Loop was buried in the cage bedding.  The animal was then returned to the cage and given 
fifteen minutes to locate the buried food.  Measures were taken of latency to find the food 
reward and whether it was consumed.   
Hotplate test for thermal sensitivity: Individual mice were placed in a tall plastic 
cylinder located on a hotplate, with a surface heated to 55
o
C (IITC Life Science, Inc., 
Woodland Hills, CA).  Reactions to the heated surface, including hindpaw lick, vocalization, 
or jumping, led to immediate removal from the hotplate.  Measures were taken of latency to 
respond.  The maximum test length was 30 sec, to avoid any type of paw damage.   
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Activity in an open field: Exploratory activity in a novel environment was assessed by a 
one-hour trial in an open field chamber (40 cm x 40 cm x 30 cm) crossed by a grid of 
photobeams (VersaMax system, AccuScan Instruments).  Counts were taken of the number 
of photobeams broken during the trial in five-minute intervals, with separate measures for 
ambulation (total distance traveled), fine movements (repeated breaking of the same set of 
photobeams), and rearing movements.  Time spent in the center region of the activity 
chamber was used as a measure of anxiety-like behavior in a novel environment. 
Rotarod: Subjects were tested for motor coordination and learning on an accelerating 
rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL).  For the first test session, animals were 
given three trials, with 45 seconds between each trial.  Two additional trials were given 48 
hours later.  Rpm (revolutions per minute) was set at an initial value of 3, with a progressive 
increase to a maximum of 30 rpm across five minutes (the maximum trial length).  Measures 
were taken for latency to fall from the top of the rotating barrel. 
Sociability: The three-chamber social approach test was designed to assess whether 
mice will approach or avoid an unfamiliar stranger mouse.  Each session consisted of two 
ten-minute phases:  a habituation period and a test for sociability.  For the sociability assay, 
mice were given a choice between being in the proximity of an unfamiliar conspecific 
(stranger 1), versus being alone.  
The social testing apparatus was a rectangular, three-chambered box fabricated from 
clear polycarbonate. Dividing walls had doorways allowing access into each chamber.  
Photocells were embedded in each doorway to allow automatic quantification of entries and 
duration in each side of the social test box.  The chambers of the apparatus were cleaned 
between each trial. 
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The test mouse was first placed in the middle chamber and allowed to explore for ten 
minutes, with the doorways into the two side chambers open.  After the habituation period, 
the test mouse was enclosed in the center compartment of the social test box, and an 
unfamiliar C57BL/6J male (stranger 1) was placed in one of the side chambers.  The stranger 
mouse was enclosed in a small wire cage, which allowed nose contact between the bars, but 
prevented fighting.  An identical empty wire cage was placed in the opposite side of the 
chamber.  Following placement of the stranger and the empty wire cage, the doors were re-
opened, and the subject was allowed to explore the entire social test box for a ten-minute 
session.  Measures were taken of the amount of time spent in each chamber and the number 
of entries into each chamber by the automated testing system.  
Acoustic startle: The acoustic startle test can be used to assess auditory function and 
sensorimotor gating.  The test is based on the measurement of the reflexive whole-body 
flinch, or startle response, that follows exposure to a sudden noise.  Assessments can be made 
of startle magnitude and of prepulse inhibition, which occurs when a weak prestimulus leads 
to a reduced startle in response to a subsequent louder noise.  For this study, animals were 
tested with a San Diego Instruments SR-Lab system.  Briefly, mice were placed in a small 
Plexiglas cylinder within a larger, sound-attenuating chamber.  The cylinder was seated upon 
a piezoelectric transducer, which allowed vibrations to be quantified and displayed on a 
computer.  The chamber included a house light, fan, and a loudspeaker for the acoustic 
stimuli.  Background sound levels (70 dB) and calibration of the acoustic stimuli were 
confirmed with a digital sound level meter (San Diego Instruments). 
Each session consisted of 42 trials that began with a five-minute habituation period.  
There were 7 different types of trials:  the no-stimulus trials, trials with the acoustic startle 
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stimulus (40 msec; 120 dB) alone, and trials in which a prepulse stimulus (20 msec; either 
74, 78, 82, 86, or 90 dB) occurred 100 ms before the onset of the startle stimulus.  Measures 
were taken of the startle amplitude for each trial across a 65-msec sampling window, and an 
overall analysis was performed for each subject's data for levels of prepulse inhibition at each 
prepulse sound level (calculated as 100 - [(response amplitude for prepulse stimulus and 
startle stimulus together / response amplitude for startle stimulus alone) x 100]. 
Morris water maze - Visible platform test:  The Morris water maze task was used to 
assess spatial learning in the mice.  The water maze consisted of a large circular pool 
(diameter = 122 cm) partially filled with water (45 cm deep, 24-26
o
 C), located in a room 
with numerous visual cues.  Mice were first tested using a visible platform.  In this case, each 
animal was given four trials on one day to swim to an escape platform cued by a patterned 
cylinder extending above the surface of the water.  For each trial, the mouse was placed in 
the pool at one of four possible locations (randomly ordered), and then given 60 seconds to 
find the visible platform.  If the mouse found the platform, the trial ended, and the animal 
was allowed to remain 10 seconds on the platform before the next trial began.  If the platform 
was not found, the mouse was placed on the platform for 10 seconds, and then given the next 
trial.  Measures were taken of latency to find the platform, swimming distance, and 
swimming speed, via an automated tracking system (Noldus Ethovision).  
Acquisition in the hidden platform test: In the week following the visual cue task, mice 
were tested for their ability to find a submerged, hidden escape platform (diameter = 12 cm).  
As in the procedure for visual cue learning, each animal was given four trials per day, with 
one minute per trial, to swim to the hidden platform.  Criterion for learning was an average 
latency of 15 seconds or less to locate the platform on one day.  Mice were tested until 
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criterion was reached, with a maximum of nine days of testing.  When criterion was reached, 
mice were given a one-minute probe trial in the pool with the platform removed.  In this case, 
selective target search was evaluated by measuring percent time spent in each quadrant, and 
the number of crossings for the target location where the platform had previously been 
located versus corresponding locations in each quadrant of the pool.   
Reversal learning:  Following the acquisition phase, mice were tested for reversal 
learning, using the same procedure as described above.  In this phase, the hidden platform 
was located in a different quadrant in the pool, diagonal to its previous location.  On the 
eighth day of testing, the platform was removed from the pool, and the group was given a 
probe trial to evaluate reversal learning. 
Locomotor behavior studies: Locomotor activity was assessed in photocell-based 
activity chambers under standardized environmental conditions using an AccuScan activity 
monitor (AccuScan Instruments, Columbus, OH) with a 41 cm x 41 cm x 30 cm Plexiglas 
chamber and a beam spacing of 1.52 cm as described (Abbas et al, 2009). Horizontal activity 
was measured as the total distance covered in centimeters as the total of all vectored X-Y 
coordinate changes and recorded in 5 minute bins.  
Spontaneous Locomotor Activity: Effect of CNO on spontaneous locomotion was 
measured during the dark phase of the light cycle to monitor behavior during a period of 
relatively high basal activity. Mice were placed in dark locomotor activity boxes at 8 pm. At 
9 pm, mice were injected with a dose of CNO and returned to the locomotor chamber for two 
hours. Novelty-Induced Locomotor Activity: A separate cohort of adora2A-rM3Ds mice and 
wild-type mice were injected with CNO (1.0 mg/kg) or vehicle or CGS 21680 (0.1, 0.5 
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mg/kg) and placed in activity boxes 20 min. later. Locomotor activity was recorded for 1 
hour.  
Amphetamine sensitization study 
Development Phase: Mice were placed in locomotor activity boxes for 1 hour to 
acclimate. Mice were then injected (i.p.) with drug(s) and/or vehicle and then returned to the 
activity chamber for 2 hours. This was repeated once daily for 5 days. Drug doses were 2.0 
mg/kg amphetamine and 1.0 mg/kg CNO. The following conditions were tested in separate 
cohorts: Cohort 1 (all adora2A-rM3Ds mice): amphetamine + CNO vs. amphetamine + 
vehicle; Cohort 2 (all wild-type mice): amphetamine + CNO vs. amphetamine + vehicle. 
Incubation phase: On days 6 – 14, mice were left in their home cages with no drug treatment. 
Expression phase: On day 15, mice were placed in locomotor chambers. One hour later, mice 
were injected with amphetamine (2.0 mg/kg) and returned to the activity chamber for 2 
hours. Locomotor activity chambers were located in a room separate from the mouse colony. 
All behavioral sensitization sessions were conducted from 1 pm to 5 pm. Data Analysis:  For 
each individual mouse, total distance travelled during the hour post injection was summed. 
Day 1 distance of a cohort was averaged, and this value was used to calculate each mouse’s 
percentage of Day 1 distance travelled. Data are presented as the average of these 
percentages. Significance was determined using a Student’s t -test on Day 15 data between 
the two conditions for each cohort.  
Electrophysiology: P23 mice were subject to the amphetamine behavioral sensitization 
procedure as detailed above. On day 15, mice were sacrificed (without drug challenge) and 
tissue preparation and recording were performed as previously described (Thomas et al, 
2001). Sagittal striatal slices (240 um in thickness) were cut containing the nucleus 
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accumbens shell. After at least one hour recovery, slices were transferred to a recording 
chamber where they were continuously perfused with oxygenated artificial cerebrospinal 
fluid containing (in mM) 124 NaCl, 2.5 KCl, 1.2 NaH2PO4, 1 MgCl2, 2.0 CaCl2, 26 
NaHCO3, and 10 glucose. Whole-cell recordings were made from rM3Ds-containing cells 
(identified by their mCherry fluorescent signals) at room temperature (24-25° C) in the 
presence of 50 uM picrotoxin and 1 uM glycine. Recording pipette resistances were 2.5–3.5 
MΩ with internal solution containing (in mM) 103 cesium gluconate, 2.8 NaCl, 5 TEA-Cl, 
20 HEPES, 0.2 EGTA, 5 lidocaine N-ethyl chloride, 4 Mg-ATP, 0.3 Na-GTP, 10 Na-
phosphocreatine and pH 7.2–7.3. Experiments were discarded if series resistance (typically 
15-20 MΩ) changed by more than 20%. Signals were low-pass filtered at 2 kHz and sampled 
at 10–20 kHz with an Axopatch 200B amplifier and a Digidata 1440A (Axon Instruments) 
for subsequent off-line analysis. To evoke excitatory postsynaptic currents (EPSCs), tungsten 
bipolar electrodes were placed at the prelimbic cortex-NAc border to stimulate afferents 
preferentially from prelimbic cortex. Stimuli with 150 μs duration were delivered at 0.05 Hz. 
AMPAR/NMDAR ratio is the ratio of the peak of the EPSC at -70 mV to the magnitude of 
the EPSC at +40 mV at 60 ms following stimulation. 
2.4. RESULTS 
2.4.1. Generation and characterization of adora2A-rM3Ds mice 
The rM3Ds is an engineered and evolved muscarinic receptor which as originally 
described: (1) selectively couples to Gαs-type G-proteins (2) is activated by the inert designer 
drug CNO and (3) is insensitive to the native ligand acetylcholine (Guettier et al, 2009). To 
determine whether the rM3Ds can activate canonical Gαs-type signaling in a neuronal 
environment, cAMP accumulation in response to increasing concentration of CNO was 
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measured in cultured neurons infected with a lentivirus expressing rM3Ds by Ying Pei 
(Figure 2b). CNO did not cause cAMP accumulation in uninfected, wild-type neurons as 
measured by Xi-Ping Huang (Figure 2e,f). Because striatal neurons express Gαolf, a Gαs-like 
G-protein enriched in striatum (Corvol et al, 2001; Drinnan et al, 1991; Zhuang et al, 2000), 
HEK-T cells were transfected with a 1:0, 1:1, and 1:3 ratio of rM3Ds to Gαolf and their 
cAMP accumulation in response to CNO measured by Vincent Setola. In Figure 2c, it can be 
seen that rM3Ds induces cAMP accumulation through the endogenous Gαs present in HEK-T 
cells in the 1:0 condition, and this accumulation is increased when Gαolf is co-transfected at 
ratios of 1:1 and 1:3. These experiments verify the functionality of rM3Ds in neurons and 
demonstrate that it can couples to both Gαs and Gαolf.  
To create striatopallidal-targeted rM3Ds transgenic mice, the adora2A BAC 
(GENSAT1-BX868) - a gene preferentially expressed in striatopallidal MSNs (Brown et al, 
2008; Chen et al, 2001) - was used to create a transgene carrying the rM3Ds construct. The 
adora2A BAC was recombineered to include an rM3Ds – IRES – mCherry construct (Figure 
2a) downstream of the adora2A start site, and mouse oocyte pronuclei were injected with the 
recombineered and purified BAC to create mice expressing rM3Ds under control of the 
adora2A BAC by Bernd Gloss at the Duke University neurotransgenic core. Three founder 
lines had detectable and essentially identical patterns of mCherry fluorescence, and the line 
denoted “AD6” was used for subsequent studies, referred to as “adora2A-rM3Ds mice”.  
Immunofluorescence microscopy revealed an expression pattern limited to the dorsal 
and ventral striata and consistent with striatopallidal projection (Figure 3a and Figure 4). 
Cell-type specificity was subsequently determined by crossing the adora2A-rM3Ds mice 
with the GENSAT Drd1a-EGFP and Drd2-EGFP reporter mice. Drd2-EGFP / adora2A-
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rM3Ds double transgenic mice displayed 82.15% (± 5.14, n=695 D2 cells in 3 mice) 
colocalization between adora2A-rM3Ds-mCherry cells and Drd2-EGFP cells (Figure 3b), 
while Drd1a-EGFP / adora2A-rM3Ds double transgenic mice show a 2.51% (±1.262, n=671 
D1 cells in 3 mice) colocalization between adora2A-rM3Ds-mCherry cells and Drd1a-EGFP 
cells (Figure 3c).  Images for the above studies were obtained by Noah Sciaky. As expected, 
there was no colocalization between parvalbumin- containing interneurons and mCherry 
(Figure 3d). These data demonstrate that the adora2A-rM3Ds mice express rM3Ds 
selectively in striatopallidal D2-dopamine receptor-expressing MSNs.  
A key signaling protein in MSNs is DARPP-32 (dopamine- and cyclic AMP-regulated 
neuronal phosphoprotein of molecular weight 32 kD) (Svenningsson et al, 2004). DARPP-32 
is directly phosphorylated at threonine 34 by protein kinase A (PKA), the canonical 
downstream effector of the Gαs/olf signaling cascade. Additionally, DARPP-32 
phosphorylation at threonine 75 is modulated by multiple extracellular signals and Thr75 
modulation can inhibit PKA. To determine whether the rM3Ds activates canonical Gαs/olf 
signaling pathways in MSNs, Tanya Daigle of Marc Caron’s laboratory tested whether CNO 
caused phosphorylation of DARPP-32 at threonine 34 and threonine 75. Mice were treated 
with CNO (5.0 mg/kg) or vehicle and striatal tissue was analyzed for pT34 DARPP-32 levels 
by Western blot analysis. It was found that CNO increased pT34 DARPP-32 levels in 
adora2A-rM3Ds mice, but not wild-type mice (Figure 5a), and no effect on pT75 DARPP-32 
levels was observed (Figure 5b). Additionally, CNO decreased pErk1/2 levels in adora2A-
rM3Ds mice, but not wild-type mice and that CNO did not cause a change in pAKT308 
levels (Figure 6). To determine whether the rM3Ds was interfering with canonical Gαs-type 
signaling in these neurons, the biochemical response to cocaine administration in adora2A-
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rM3Ds and wild-type mice was measured. No difference in cocaine-induced DARPP-32 
Thr34 levels between wild-type and adora2A-rM3Ds mice (Figure 7) was observed. These 
findings demonstrate that rM3Ds activates canonical Gαs-type signaling pathways in vivo and 
indicate that the endogenous signaling mechanisms are not disturbed. 
To determine whether the adora2A-rM3Ds transgene had any CNO-independent 
activity that significantly altered behavior, transgenic mice and litter-mate controls were 
tested in a battery of behavioral tests in their naïve state without CNO treatment by Randal 
Nonneman of Sheryl Moy’s laboratory. In comparison to wild type litter-mates, adora2A-
rM3Ds mice did not have significant differences in weight, locomotion, rotarod performance, 
prepulse inhibition, Morris water maze performance, sociability, elevated plus maze 
performance, olfaction or thermal sensation (Figure 8 tables 2,3). To determine whether the 
presence of the striatopallidal rM3Ds influenced endogenous Gαs-type signaling, adora2A-
rM3Ds and wild-type mice were injected with vehicle, 0.1, or 0.5 mg/kg CGS21680, a 
selective agonist for the adenosine A2A receptor, and placed in a locomotor chamber 20 
minutes later to record novelty-induced locomotor activity (Figure 9). A two-way ANOVA 
indicated a significant effect of dose (p < 0.05) but not genotype or interaction (p=0.66 and 
p=0.51, respectively). These data indicate that in the absence of designer drug activation 
(CNO), the presence of the adora2A-rM3Ds transgene does not significantly alter mouse 
behavior. Combined, these control studies establish the suitability of adora2A-rM3Ds mice to 





2.4.2. CNO-induced modulation of locomotion in adora2A-rM3Ds mice 
Striatopallidal medium spiny neurons of the indirect pathway are thought to exert an 
inhibitory effect on locomotor behavior when activated (Albin et al, 1989; Alexander and 
Crutcher, 1990; DeLong, 1990; Kravitz et al, 2010). To determine whether rM3Ds activation 
in striatopallidal MSNs inhibits locomotion, adora2A-rM3Ds mice were injected with CNO 
(1.0 mg/kg) and placed into a novel open field testing chamber 20 minutes later. CNO 
treatment of transgenic, but not wildtype, mice robustly decreased locomotion (Figure 10a). 
Similar effects and a dose dependency were demonstrated by testing spontaneous locomotion 
during the active period (dark phase) of the diurnal cycle (Figure 10b,c). These two data sets 
indicate that Gαs/olf-activation in striatopallidal neurons of adora2A-rM3Ds mice is sufficient 
to inhibit locomotion.  
2.4.3. CNO-induced modulation of amphetamine sensitization 
In rodent models, repeated exposure to psychostimulants produces an enhanced 
behavioral responsiveness, known as behavioral sensitization (Steketee and Kalivas, 2011). 
Amphetamine causes an increase in synaptic dopamine release, thereby inducing excessive 
stimulation of the D1- and D2-dopamine receptors (McKenzie and Szerb, 1968; Sulzer, 
2011). The increased locomotor effects produced in behavioral sensitization may thus arise 
as a result of Gαs/olf signaling in D1R-containing striatonigral MSNs, Gαi signaling in D2R-
containing striatopallidal MSNs, or a combination of these two effects. A potential role for 
Gαs-type signaling in striatopallidal neurons in amphetamine-induced behavioral 
sensitization is suggested by pharmacological studies in rodents in which an A2AR agonist 
during the development phase inhibits sensitization (Shimazoe et al, 2000).  Given these 
observations, I tested whether rM3Ds activation during development of amphetamine 
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sensitization significantly altered behavioral sensitization. Mice were administered 
amphetamine (2.0 mg/kg) with or without CNO (1.0 mg/kg) for five days and their 
locomotor activity recorded. Mice were then given a 10 day “break” period and the 
expression of sensitization was tested on day 15 by the administration of amphetamine (2.0 
mg/kg) and vehicle. When CNO was co-administered with amphetamine in adora2A-rM3Ds 
mice during development, behavioral sensitization was inhibited (Figure 11a, red line and 
box). In contrast, wild-type mice treated with amphetamine, wild-type mice treated with 
amphetamine and CNO, and adora2A-rM3Ds mice treated with amphetamine alone all had 
normal sensitization (Figure 11a). These data indicate that (1) rM3Ds activation blocks 
development of amphetamine sensitization, (2) in the absence of CNO adora2A-rM3Ds mice 
sensitize normally to amphetamine, and (3) that CNO does not have off-target effects. Lastly, 
these findings were replicated in an independent founder line of adora2A-rM3Ds mice 
(Figure 12). 
In the nucleus accumbens, behavioral sensitization to psychostimulants can be 
accompanied by long-lasting changes in fast glutamatergic synaptic transmission (Bowers et 
al, 2010; Thomas et al, 2001; Wolf and Ferrario, 2010). Thus, we investigated whether 
repeated rM3Ds activation during the amphetamine sensitization protocol induced long 
lasting changes in glutamatergic synaptic transmission in adora2A MSNs of adora2A-rM3Ds 
mice. Three week old mice (to facilitate whole cell recordings) were treated with 
amphetamine daily for 5 days along with CNO (1mg/kg) or vehicle as done in the behavioral 
sensitization paradigm described above. On day 15, mice were sacrificed (without 
amphetamine challenge) and excitatory postsynaptic currents (EPSCs) of mCherry-
expressing (transgene marker) MSNs in the nucleus accumbens shell of acute brain slices 
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were measured by Yehong Wan of Nicole Calakos’s laboratory. Under recording conditions 
in which responses of AMPA- (2-amino-3-(5-methyl-3-oxo-1,2- oxazol-4-yl) propanoic acid) 
and NMDA- (N-Methyl-D-aspartic acid) type glutamate receptors (AMPAR and NMDAR, 
respectively) could be compared, it was found that CNO treatment during induction of 
behavioral sensitization caused a significant and long-lasting increase in the 
AMPAR/NMDAR ratio compared to amphetamine treatment alone (p=0.006, t-test; p=0.016, 
rank test) (Figure 11b). Of note, relative to non-sensitized (saline) controls, the effects of 
amphetamine on the AMPAR/NMDAR ratio trended in opposite directions depending on the 
presence or absence of CNO. Treatment with amphetamine alone trended to decrease the 
AMPAR/NMDAR ratio compared to saline (p = 0.108, two-tailed t-test; p=0.100, rank test), 
whereas treatment with amphetamine and rM3Ds activation by CNO trended to increase the 
ratio compared to saline (p=0.108, two-tailed t-test; p=0.184, rank test). These data 
demonstrate that concurrent activation of rM3Ds during amphetamine sensitization is 
accompanied by long lasting changes in synaptic strength of adora2A MSNs that oppose the 
effects of amphetamine alone. 
 
CHAPTER 3. GENERAL DISCUSSION, IMPLICATIONS, AND FUTURE 
DIRECTIONS 
3.1. DISCUSSION 
Although striatal GPCR signaling has been studied for decades, the role of whole-
striatum, cell type-specific, GPCR-mediated signaling on behavior remains unknown and has 
been heretofore unknowable. Using a newly developed mouse model in which I selectively 
and stably expressed a Gs-DREADD (rM3Ds) in striatopallidal neurons, I have validated the 
use of the DREADD technology to non-invasively control Gs-type signaling in a neuronal 
context in vivo. Because of the non-invasive spatio-temporal control afforded, DREADD 
technology has far-reaching applicability to test the role of GPCR activity in a broad array of 
neuronal and non-neuronal contexts. In this report, I further demonstrate that Gs-DREADD is 
well-tolerated when expressed long-term in a transgenic context and this construct can be 
used in future studies to reveal new insights on the cellular and behavioral significance of 
Gs signaling in defined cellular populations. 
Since the introduction of the DREADD technology, several independent groups have 
reported success activating and silencing neurons with hM3Dq and hM4Di respectively 
(Alexander et al, 2009; Ferguson et al, 2011; Garner et al, 2012; Krashes et al, 2011; Ray et 
al, 2011; Sasaki et al, 2011), but have not explored the slow neurotransmission-type Gαs/olf-
mediated signaling.  In this report, I demonstrate the suitability of DREADD technology to 
manipulate the Gαs/olf-mediated signaling pathway in neurons and thereby modulate 
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behavior. My evidence for this is as follows: adora2A-M3Ds mice, when administered CNO, 
(1) show increased DARPP-32 phosphorylation indicative of MSN Gαs/olf activity; (2) show a 
dose-dependent decrease in locomotor activity; and (3) show a blunted behavioral 
sensitization response to amphetamine indicative of long-term Gαs-induced modulatory 
effects in striatopallidal MSNs. Additionally, these findings complement recent evidence that 
selective perturbation of D1 MSN activity influences behavioral sensitization (Pascoli et al, 
2012). In this dissertation, I found that manipulations specifically targeting A2AR MSNs are 
also sufficient. Moreover, the findings of the two studies are parsimonious with the idea of 
opposing effects of D1R and A2AR MSNs on motor activity.  D1 MSN synaptic weakening 
inhibited expression of behavioral sensitization (Pascoli et al, 2012), and we find that A2AR 
MSN synaptic strengthening is sufficient to block behavioral sensitization. 
It is important to note the differences between the pharmacosynthetics and the 
optogenetic approaches to remotely control neuronal activity. Differences in the technical / 
methodological considerations have been previously discussed, as have differences in the 
type of signaling afforded by these technologies (Alexander et al, 2009; Rogan and Roth, 
2011). A key difference not fully appreciated is the nature of the neuronal modulation 
provided by these two technologies. Pharmacosynthetics provides a system that more closely 
resembles the hormonal signaling mechanisms found in the brain, whereas optogenetics more 
closely resembles electrochemical signaling phenomena. These differences should 
fundamentally affect the type of experimentation performed with the respective technologies. 
To date, the implementation of pharmacosynthetics as “synthetic pharmacology” has yet to 
occur, in that the modulation afforded by peripheral CNO administration – bathing the brain 
with modulator – and the corresponding widespread DREADD expression afforded by 
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genomic transgene expression closely resembles pharmacotherapeutic drug action. Potential 
applications of this aspect can be further appreciated by the fact that DREADDs are 
engineered GPCRs, and GPCRs are the target for more than 50% of currently prescribed 
psychiatric therapeutics (Roth et al, 2004). In this regard, the differences between the two 
technologies can be observed as differences in scientific objectives: pharmacosynthetics is 
best suited for the study of how drugs modulate the function of the brain 
(neuropharmacology), whereas optogenetics is best suited for the study of brain function 
itself (neurophysiology).  
In conclusion, I here provide the first evidence that the Gs-DREADD technology can 
afford modulation of in vivo neuronal populations in a reproducible and non-invasive 
manner, and thereby providing the neuroscience community with a new tool to selectively 
and non-invasively modulate Gαs signaling in a neuronal cell type -specific manner.  
3.2. IMPLICATIONS  
3.2.1. Regarding Technological Validation 
As mentioned before, the nature of modulation afforded via pharmacosynthetics is more 
nuanced than merely turning “on” or “off” a neuron. This is especially true regarding Gs type 
G protein signaling, which cannot claim the relatively straightforward biochemical signaling 
pathway towards neuronal excitation or inhibition of the other DREADDs (hM3Dq ► Gq ► 
PLC ► IP3 ► Ca2+ ► neuronal firing; hM4Di ► Gβ/γ ► GIRK ► K+ ► neuronal 
silencing). The findings of my research prove that the rM3Ds is an effective means to control 
neuronal Gs-type signaling, and this validation will enable further research into Gs-type 
modulation of neurons.  
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3.2.2. Regarding Neurobiological Findings 
The observation that selective striatopallidal Gs signaling can inhibit the development 
of behavioral sensitization caused by repeated amphetamine administration suggests that 
coactivation of striatopallidal Gs signaling may be an effective means to prevent the 
development of drug addiction. Indeed, adenosine A2A receptors have been investigated as 
targets for drug addiction pharmacotherapeutics (Filip et al, 2012). This previous research, in 
addition to the findings of my dissertation research, led me to test the ability of striatopallidal 
rM3Ds signaling to block another behavioral model of drug addiction, conditioned place 
preference (CPP). In CPP, the pairing of a rewarding drug with a unique environment causes 
an animal to seek that particular environment in a drug free state, suggesting that the drug has 
produced a pleasurable effect in the animal. Compared to behavioral sensitization, CPP is 
thought to have greater construct validity as it recapitulates the rewarding properties of drug 
administration (Bardo and Bevins, 2000). Preliminary results suggest that same concurrent 
striatopallidal Gs signaling utilized in my behavioral sensitization experiments does not 
block the development of an amphetamine conditioned place preference. The correspondence 
between behavioral sensitization and conditioned place preference has been a cornerstone of 
addiction research for decades as a key behavioral manifestation of the “Incentive-
Sensitization Theory” of drug addiction (Robinson and Berridge, 1993). These preliminary 
results suggest that selective activation of striatopallidal MSN Gαs signaling differentially 
affects these two behavioral paradigms for drug addiction. These findings suggest that 
enhanced striatopallidal Gαs-signaling can separate the behavioral-sensitization aspects from 
the rewarding aspects of amphetamine, a finding that could have implications for drug 
addiction. For instance, if similar findings are observed when studying opiate-induced 
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phenomena, these findings could lead to the development of analgesic adjuvants that prevent 
the development of prescription opiate addiction.  
In the literature, the leading hypothesis of adenosine A2A receptor modulation on 
addiction-type behaviors is centered on a proposed dopamine D2 receptor / adenosine A2A 
receptor heterodimer (Ferre et al, 2008). The findings of the amphetamine sensitization 
studies suggest that striatopallidal Gs-type signaling is sufficient to block amphetamine 
behavioral sensitization independent of a heterodimer. Although I did not directly test this 
hypothesis, for example, by determining whether the rM3Ds forms heterodimers with 
dopamine D2 receptors, the nature of the DREADD manipulation implies that the effects on 
amphetamine sensitization were due to downstream biochemical signaling events as opposed 
to steric receptor influences. This avenue of inquiry could be a fruitful direction of future 
research DREADDs in general, and the adora2A-rM3Ds mice in particular.  
 
3.3. FUTURE DIRECTIONS 
3.3.1. Future technological development 
My dissertation research was focused on the validation of a new technology. Therefore, 
I believe that one of the most relevant future directions is that of further development of the 
pharmacosynthetic approach. These future developments will permit this technology to have 
broader and greater impacts in the field of neuropharmacology.  
3.3.1.1. A non CNO-based DREADD 
First and foremost, the development of a second, non CNO-based DREADD would be 
the most advantageous development to further our neuropharmacological understanding of 
the brain. The availability of an additional DREADD could permit the mapping of functional 
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neuronal circuits, for example, by placing an excitatory non CNO-based DREADD upstream 
of a nuclei modulated by the hM4Di. In this fashion, one could determine the functional 
involvement of a series of nuclei posited to be integral for a given neuronal circuit. Indeed, 
the Roth laboratory has recently created a new Gi-biased DREADD to this end (Vardy et al, 
in preparation).  
3.3.1.2. Enhanced genetic expression strategies 
The cell-type specificity afforded by the pharmacosynthetic approach is dependent upon 
the available genetic targeting approaches. As mentioned above, virally mediated gene 
transfer provides for the most effective targeting of small nuclei, whereas genomic 
modification approaches are the most non-invasive means to obtain cell-type specific 
DREADD expression, though the expression patterns obtained can be off-target (due to the 
nature of the gene promoter used). Furthermore, existing technologies have been designed to 
be versatile as opposed to specific, creating scenarios in which multiple transgenes must be 
present in a mouse to confer DREADD expression or generations of germline recombination 
must be undertaken to obtain a useable mouse. Ideally, a DREADD could be expressed in the 
intended neuronal population using as few transgenes as possible. This both simplifies mouse 
breeding requirements and would “future proof” a given mouse line. E.g., if a single 
transgene mouse was created that expressed a DREADD in a specific population, a second 
transgenic mouse carrying a non CNO-based DREADD could be crossed with this mouse. 
Thus, one could have two different DREADDs expressed using only two transgenes.   
3.3.1.3. Complete experimental control of signal transduction 
The supposition that signal transduction can be separated from the physiological 
response, in addition to the implications of functional selectivity, necessitate a further 
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rightward shift in our control and understanding of the pharmacological equation. Whereas 
the pharmacosynthetic state of the art currently provides for control of the ligand-receptor 
pair, the physiological response is still dependent on the effectors present in a given cell type. 
In the future, it may be possible to control the ligand-receptor-effector triplet (or the ligand-
receptor-effector-effector quartet, etc), providing unprecedented depth of pharmacological 
manipulation as was recently described by Yagi et al, (2011). For instance, one can imagine 
creating polycistronic transgenes that contain custom effectors designed to solely interact 
with designer receptors (Figure 13c). In this manner, one could truly synthesize signaling 
states in specific cell populations to create an end-goal for pharmacotherapeutic 
development. These custom signaling cascades will provide an unprecedented level of 
signaling control and definitively determine the type of signaling required for a particular 
physiological response.   
 
3.3.2. Future Applications of Pharmacosynthetic Technology 
Pharmacosynthetics has untapped potential. The utilities not yet applied are inherent to 
the nature of GPCR signaling in general and that of the pharmacosynthetic approach itself. 
With the advent of more specific cell-type expression and measurement systems, DREADD 
technology can be utilized to probe the mechanisms of pharmacotherapeutic efficacy and the 
nature of GPCR-induced neuronal modulation. Here I will discuss currently underutilized 
aspects of pharmacosynthetics.   
3.3.2.1. Non-interfering modulation 
An overlooked aspect of the pharmacosynthetic approach is the lack of interference 
with endogenous signaling. Whereas the noninvasive aspect relates to the physiologically 
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benign approaches of DREADD expression (transgenic mice), this lack of interference 
relates to the nature of the experimental manipulation.  
It has been posited elsewhere that the ultimate function of the brain arises from the 
collection, transmission, and integration of information (deCharms and Zador, 2000; Rolls 
and Treves, 2011). The brain encodes this information in the biochemical and 
electrochemical phenomena of neurons, with the transmission and integration occurring 
through the function of action potentials, neurotransmitters, and receptors. Various nuclei in 
the brain have been implicated in the etiology of disease and the mechanism of action of 
therapeutics. Due to the limitations of conventional approaches, it is difficult to separate the 
role of a nuclei’s transmission, integration, or generation of information in the etiology of the 
associated diseases. For example, in a standard pharmacological approach, a small molecule 
ligand would be used to modulate a particular receptor. In addition to inherent off-target 
confounds of this approach, receptor theory posits that any small molecule will compete with 
the endogenous ligand for that receptor, ultimately functioning as an antagonist of the 
endogenous tone. This confound applies to allosteric modulation as well. Whereas 
measurements from such a study would implicate the role of receptor-mediated changes in 
the postsynaptic neuron, the phenomena observed may be due, in part, to interference with 
the endogenous tone of ligand-receptor signaling. Thus, the interpretation of such a study 
would not be able to resolve whether the experimental manipulation modulated the integrator 
and transmitter of information (the post-synaptic cell receiving input) or the information 
itself (the endogenous tone).  
Pharmacosynthetics circumvents this confound by utilizing an exogenous receptor, 
leaving the endogenous tone intact. This aspect of the DREADDs has been studied in vitro, 
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where the hM3Dq (with or without CNO) had minimal or no effect (dependent on 
measurement system used) on the quaternary organization of wild-type and DREADD 
variants (hM3 and hM3Dq) of the human muscarinic receptor (Alvarez-Curto et al, 2010). 
Furthermore, the inert clozapine N-oxide does not interfere with endogenous receptor 
signaling. In this manner, the experimenter can specifically modulate the neuronal nuclei in 
question, independent of the information transfer. This non-interference of experimental 
manipulation has yet to be explicitly utilized or considered in experimental design using the 
DREADDs.  
3.3.2.2. Cell-type specific GPCR signaling vs. “activation” and “silencing” 
A majority of the studies to date have been designed and the data interpreted in the 
context of DREADD-induced activation or silencing of neuronal activity. Whereas a result of 
Gαq-coupled GPCR activation is depolarization and a result of Gαi-coupled GPCR activation 
is hyperpolarization, these electrophysiological endpoints are only one result of GPCR 
signaling pathways (Allen and Roth, 2011; Beaulieu et al, 2011). In the pharmacosynthetic 
field, other physiological endpoints have heretofore been, for the most part, overlooked. G-
protein pathways are involved in a myriad of neuronal functions, including gene regulation 
(West et al, 2002). Indeed, whereas the straightforward interpretation and design of Gαq-
mediated depolarization and Gαi-mediated hyperpolarization is pragmatic for studies to date, 
the inherently metabotropic nature of GPCR signaling needs to both be utilized and taken 
into account when considering pharmacosynthetics for experimental manipulation.  
An application of pharmacosynthetics that would utilize this facet of DREADDs is 
determining the particular G-protein signaling necessary for therapeutic efficacy. The advent 
of functional selectivity has caused a sea change in our understanding of GPCR function, in 
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that the simple distinction of ligands as agonists, antagonists, and inverse agonists no longer 
exists (Allen et al, 2011; Urban et al, 2007). Instead, it is now appreciated that a particular 
small molecule can impart intracellular signaling entirely dependent on the signaling 
machinery present in a given cell type. Thus, a given “agonist” to a receptor in cell 
population A can induce receptor-mediated signaling, whereas the same “agonist” at the same 
receptor in cell population B can have no effect or a different effect entirely. Furthermore, the 
observed phenomena to date suggest that the signaling induced upon ligand binding is 
dependent on the small molecule - a particular “agonist” X to a receptor can induce a 
particular GPCR-mediated signaling phenomenon (such as cAMP accumulation), whereas 
another “agonist” Y at the same receptor can cause entirely different GPCR-mediated 
signaling phenomenon (such as beta-arrestin signaling). This “functional selectivity” of small 
molecule ligands opens a new chapter in small molecule drug discovery for G-protein 
coupled receptors, an already well-validated drug targeted.  
This new effort is hindered by an unfortunate fusion of the phenomena to be exploited 
and the nature of modern drug discovery efforts. To date, a majority of drug discovery efforts 
use cultured cell populations as a model system to study GPCR signal transduction. In what 
is termed “reverse pharmacology”, a receptor is isolated from the organism and its signal 
transduction properties are studied in the cultured cell populations (Figure 14, top). Due to 
the implications of functional selectivity, these cultured cell populations, in combination with 
the type of GPCR being studied and the chemical space of the drug, synergize to produce the 
signaling phenomena observed. Thus, the observed phenomena are dependent upon the 
model cell system used. Any subsequent translation of a drug’s function to the whole 
organism is due to a fortuitous similarity of cellular phenotype between the model system 
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and the whole organism. While reverse pharmacology has created a wealth of information 
regarding the relationships between the structure of a small molecule ligand and the response 
of the receptor, the translation of these findings to the whole organism, in terms of 
therapeutic efficacy, has been less fruitful.  A well-known contributor to inverse 
pharmacology’s lack of success is that these chemicals can have off-target effects when 
reintroduced to the whole organism. While this confound is measurable and perhaps rectified 
with further compound development, a second unmeasurable confound is the differential 
receptor function in the native cellular environment compared to the cultured cell. Whereas a 
chemical may induce a unique signaling state when it is bound to a receptor in the model cell 
culture system, the native neuronal environment of the receptor may not have cellular factors 
capable of recognizing the signal being transduced  by the chemical-receptor complex (for 
review see Allen and Roth 2011).  
Pharmacosynthesis creates a means to overcome this confound. The opposite approach 
to reverse pharmacology can be termed “directed” pharmacology, in which the signaling of a 
particular receptor is designed and characterized in the cultured cell system and then 
introduced into the whole organism (Figure 14, bottom). An aspect of the DREADDs not 
fully appreciated is the fact that mutations used to engender CNO modulation and rectify 
endogenous neurotransmitter modulation are functionally benign. That is, the receptor 
behaves for all intents and purposes identical to the wild-type receptor (Alvarez-Curto et al, 
2011). This facet of DREADDs permits the manipulation of intracellular receptor 
components that can affect the coupling of the receptor to downstream effectors. Guettier et. 
al. (2009) recognized this and swapped the intracellular loops of the hM3Dq with the loops 
of the turkey β1-adrenergic receptor to confer Gs-coupling of the DREADD. Although the 
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exact mechanism of ligand induced GPCR activation is unknown, it has been hypothesized to 
be a shared mechanism across GPCRs. For instance, many groups have reported creating 
chimeras of the transmembrane and extracellular portions of GPCR type A with the 
intracellular portions of GPCR type B to confer type B receptor signaling following 
application of ligands for receptor type A (Kim et al, 2005; Marion et al, 2006; Oh et al, 
2010). If this holds true across receptor types, one can hypothesize that the intracellular 
components of a DREADD can be replaced with those of a different receptor to confer CNO 
modulation of that receptor’s signaling. DREADDs could be designed to modulate unique 
and specific signal transduction pathways in cell culture systems, and then these DREADD 
variants could be inserted in vivo to determine whether the designed functional selectivity 
translates into usefully different neuronal signaling and function (Figure 14E-G). Because the 
specificity of CNO for the DREADD is pharmacologically unprecedented, this approach 
would allow us to introduce designer signaling into specific cell types and study the 
subsequent physiological response to this signaling.  Indeed, recent efforts have culminated 
in the creation of optically activated β-arrestin functionally-selective DREADDs (Lee and 
Roth, in preparation; Nakajima and Wess (2012)) which allow for the precise spatio-
temporal control of arrestin signaling.  
In one sense, this potential application can invert our standard means of molecular 
pharmacology. Instead of isolating the signal transduction device (the GPCR) and studying 
its effects on non-native signal transduction cascades (Figure 14A,B), we can now study the 
ligand-receptor complex as a single entity. The results of these studies will be correlative 
information between the signaling transduction induced by CNO/DREADDs in model cell 
systems and the physiological response of the CNO/DREADDs in the whole organism 
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(Figure 14E,F). These data could then be used to design small-molecule ligands (or 
collections of small molecule ligands) that mimic the CNO/DREADD signaling phenomena 
observed in the cultured cell system (Figure 14I). This approach would essentially invert the 
process of drug discovery: instead of designing a chemical to elicit an efficacious 
physiological response, we could directly design an efficacious signaling state and then 
create a chemical (or chemicals) that can recapitulate the designed state. To our knowledge, 
only the DREADD technology provides this utility, capitalizing on the drug-like modulation 
of selective but dispersed neuronal populations.  
3.3.3. Future Neurobiological Directions 
The findings related to drug addiction warrant further investigation utilizing DREADDs 
to determine the role of cell type specific G protein signaling in addiction etiology. The 
preliminary conditioned place preference findings should be followed, and the effects of 
striatopallidal Gs signaling on drug self-administration should be studied to further clarify the 
effects of this signaling on drug addiction phenomena. By studying the effects of 
striatopallidal Gs signaling in this suite of addiction paradigms using the adora2A-rM3Ds 
mice, we can advance our understanding of addiction etiology.  
 
3.4. FINAL WORDS: 
Pharmacosynthetic technology provides the means to advance our understanding of 
drug pharmacology and the underlying physiology of pharmacologically tractable systems. 
This dissertation provides neuronal validation of the rM3Ds, a Designer Receptor 
Exclusively Activated by Designer Drug (DREADD) that specifically modulates Gs-type G-
alpha proteins. The further development of pharmacosynthetic tools will enable more precise 
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manipulation of biochemical signaling phenomena, allowing neuropharmacologist to 
advance towards connecting the signal to the physiological response. Ultimately, these 
advances may lead to the development of better and more efficacious therapeutics. 
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APPENDIX A. TABLES 
Table 1: Summary of neuronal DREADD applications to date. 
 
This table provides a quick reference for all neuroscience research performed to date 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2: Baseline Behavior Activity 
 
adora2A-rM3Ds transgenic mice and wild-type mice show similar behavioral activity in 
the elevated plus maze, olfactory test, and hotplate test. Data shown are means ± SEM, n=12 
for each genotype. 
 
Behavioral Measure Wild-type Adora2A-rM3Ds 
Elevated plus maze   
     Percent time in the open arms 19.1% ± 3.8 20.7% ± 3.5  
     Percent entries into the open arms 24.5% ± 3.7 27.3% ± 3.1      
     Total number of entries 19.9 ± 1.7 21.3 ± 2.0 
Olfactory test   
     Latency to find the buried food (sec)      24.8 ± 5.3 20.2 ± 4.6
a
 
     Percent of group finding the food 100% 92% 
Hotplate test   
     Latency to respond (sec) 15.3 ± 1.7    14.6 ± 1.2 
a
The data from one adora2A-rM3Ds mouse with an extreme score (900 sec) was removed 








Table 3: Baseline Morris Water Maze:  
adora2A-rM3Ds transgenic mice and wild-type mice show similar behavioral 





Latency to escape (sec) 12.0 ± 1.2 15.4 ± 1.4 
Swimming distance (cm) 202.7 ± 18.2 245.7 ± 26.8 















Figure 1: Properties and Composition of Currently Utilized DREADDs.  
(A) Gray box indicates two-way selectivity component of DREADDs. Solid lines with 
arrows indicate that the source compound activates the receptor at the arrow’s target. Dashed 







Figure 2: Creation and validation of adora2A-rM3Ds mice.  
(a) Schematic of rM3Ds-IRES-mCherry construct that was recombineered into the 
adora2A BAC. (b) Activation of rM3Ds by CNO in rat cortical neurons infected with 
FUGW-rM3Ds-IRES-mCherry causes a concentration-dependent increase in cAMP 
accumulation (n=3). (c) Increasing concentrations of Gαolf plasmid relative to rM3Ds-IRES-
mCherry plasmid increase cAMP accumulation in response to CNO application (n=3). (d) 
Genotyping band for adora2A-rM3Ds mice. Lanes 1 & 2 are of adora2A-rM3Ds mice. Lanes 
3 & 4 are of wild-type mice. A band in adora2A-rM3Ds mice is seen at approximately 250 
















(a) Sagittal whole-brain expression pattern of adora2A-rM3Ds mice. (b) Representative 
immunohistochemistry for mCherry (red) and EGFP (green) in adora2A-rM3Ds / Drd2-
EGFP double transgenic mice. (c) Representative immunohistochemistry for mCherry (red) 
and EGFP (green) in adora2A-rM3Ds / Drd1a-EGFP double transgenic mice. (d) 
Immunohistochemistry for mCherry (red) and parvalbumin interneurons (green).   
 
Figure 3: rM3Ds is expressed in striatopallidal neurons in adora2A-rM3Ds mice. 
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Figure 4: Additional immunohistochemistry images comparing a wild-type mouse with 
an adora2A-rM3Ds transgenic mouse.  
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.  
Figure 5: CNO activates canonical Gαs-type signaling in adora2A-rM3Ds mice.  
CNO (5.0 mg/kg) increases pT34 DARPP-32 levels in the ventral striatum of adora2A-
rM3Ds mice but not WT mice. Representative Western blots of pT34 DARPP-32 levels in 
adora2A-rM3Ds transgenic mice administered CNO (5.0 mg/kg) or vehicle are shown. 







Figure 6: pErk1/2 and pAkt308 signaling in adora2A-rM3Ds mice.  
Western blot analysis of (A) pErk1/2 and (B) pAkt308 levels from adora2A-rM3Ds 
(GsD) and wild-type (WT) mice administered CNO 5.0 mg/kg or vehicle. Data are presented 




















Figure 7: Cocaine-induced signaling in wild-type and adora2A-rM3Ds mice. 
Western blot analysis of (A) pT34 DARPP-32 levels from adora2A-rM3Ds (GsD) and 









Figure 8: Results of baseline behavior screen.  
(A) Weights of mice in grams during behavioral testing.  Data shown are means (± 
SEM) for each group. (B) Amplitude of the startle response and (C) prepulse inhibition 
following presentation of acoustic stimuli.  Data shown are means (+ SEM) for each group.  
Trials included no stimulus (No S) trials and acoustic startle stimulus (AS) alone trials. (D) 
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adora2A-rM3Ds (Ds TG) mice have normal locomotion and (E) anxiety-like behavior in a 
novel environment.  Data shown are means (± SEM) for a one-hour test session. (F) Latency 
to fall from an accelerating rotarod.  Data shown are means (+ SEM) for each group.  Trials 4 
and 5 were given 48 hours after the first three trials. (G) Acquisition and (H) reversal 
learning in the Morris water maze.  Data shown are mean (± SEM) of four trials per day. (I) 
Time spent in each of the side chambers and (J) sniffing the two cages during the test for 
sociability.  Data shown are mean + SEM for each group for a 10-min test.  * p < 0.05, 

















Figure 9: Endogenous Gs signaling is intact in adora2A-rM3Ds mice.  
Wild-type and Adora2A-rM3Ds mice show no difference in novelty-induced locomotor 
activity suppression caused by the adenosine A2A agonist CGS 21680. Data are presented as 






Figure 10: CNO administration inhibits locomotor activity in adora2A-rM3Ds mice.  
(a) CNO blocks novelty-induced locomotor activity. Inset – bar graph representation of 
data summed over time. Data are presented as distance travelled (cm) in 5 minute bins ± 
s.e.m. starting 5 minutes after placement into chamber. Histogram is the total distance 
travelled as summed from minute 5 to minute 45 ± s.e.m. (b) Bar graph representation of 
dark-phase locomotor activity summed for 100 minutes post-injection. Data are presented as 
total distance travelled as summed for 100 minutes starting 10 minutes after injection ± 
s.e.m. (c) CNO inhibits dark-phase spontaneous locomotor activity, time course. Data are 
presented as distance travelled (cm) in 5 minute bins ± s.e.m. *p<0.05; two-tailed t test, n=4. 
**p<0.005; two-tailed t test, n=8 
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Figure 11: CNO administration modulates amphetamine-induced physiological 
changes.  
(a) Co-administration of CNO (1.0 mg/kg) blocks the development of behavioral 
sensitization caused by amphetamine (2.0 mg/kg) in adora2A-rM3Ds mice. Data shown are 
mean percentage of day 1 total horizontal distance traveled over 60 min (+/- SEM). (b) CNO 
 80 
+ AMPH increases the AMPAR/NMDAR receptor ratio in adora2A MSNs of the NAc shell 
relative to AMPH alone treated mice on day 15. Stimulus intensity was set to obtain an 
evoked AMPAR EPSC of about 70 pA at -70 mV for all three conditions. Scale bar: 25 pA 
and 20 ms. Sample traces shown on top. All data are presented as means ± s.e.m. *p<0.05; 











Figure 12: Replication in second founder line.  
A second founder line (AD8) of the adora2A-rM3Ds transgenic mouse line exhibits a 
similar phenotype in the amphetamine (2.0 mg/kg) behavioral sensitization paradigm in 
response to CNO (1.0 mg/kg) administration. Data are presented as percent day 1 average 

















Figure 13: Shifting the pharmacological equation.  
(A) The conventional understanding of pharmacology posits that drugs interact with 
physiological systems to produce a physiological response. This interaction takes place 
through the transduction of a signal (either an endogenous chemical or an exogenous drug) 
via signal transduction mechanisms. The current depth of pharmacology defines the signal as 
the ligand itself, freeing the signal transducer and the signal transduction cascade to blend 
with the physiological response. (B) Pharmacosynthetic depth of pharmacology. Using 
pharmacosynthetics, both the ligand and the signal transducer (receptor) shift to the left side 
of the equation, creating a more defined signal with less signal transduction noise. (C) Future 
Pharmacosynthetics. With further development, a deeper level of pharmacosynthetic 
manipulation can be obtained. With the entirety of the signal transduction cascade under 
experimental control, we could potentially understand the type of signal needed to evoke a 















Figure 14: An application of pharmacosynthetics in drug discovery.  
(A-D) Conventional drug discovery efforts – reverse pharmacology. In this approach, a 
drug target is selected (usually based on previous success at that particular target) and 
isolated from the organism. A particular type of signaling is hypothesized to be efficacious, 
and chemicals are created that cause the receptor to produce that signaling state in cultured 
cells. The drug is then reintroduced to the model organism and tested for therapeutic efficacy. 
(E-I) A theoretical workflow of drug discovery efforts using pharmacosynthetics, here 
termed direct pharmacology. In this approach, functionally selective DREADDs ( 
f(x)DREADD, where x=signaling type) are created by modifying DREADDs to modulate 
distinct signaling phenomena in cultured cells while maintaining their DREADD properties. 
These f(x)DREADDs are then expressed in therapeutically relevant neuronal populations. 
These mice are then tested in animal models of therapeutic efficacy. If a particular 
f(x)DREADD in a particular neuronal population is efficacious, then that cell population is 
profiled to find druggable targets. These druggable targets are then isolated (expressed in 
cultured cells) and chemicals are created that modulate these targets to reproduce the 
signaling state created by the f(x)DREADD. Chemicals that successfully recapitulate the 
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